{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:54:35Z","timestamp":1793523275976,"version":"4.5.0"},"reference-count":302,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>\n                    Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new uterine cancer cases will have occurred in 2022, with 12,550 deaths resulting from the disease. Endometrial carcinoma includes pure endometrioid cancer and carcinomas with high-risk endometrial histology (including uterine serous carcinoma, clear cell carcinoma, carcinosarcoma [also known as malignant mixed M\u00fcllerian tumor], and undifferentiated\/dedifferentiated carcinoma). Stromal or mesenchymal sarcomas are uncommon subtypes accounting for approximately 3% of all uterine cancers. This selection from the NCCN Guidelines for Uterine Neoplasms focuses on the diagnosis, staging, and management of pure endometrioid carcinoma. The complete version of the NCCN Guidelines for Uterine Neoplasms is available online at\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/NCCN.org\">NCCN.org<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2023.0006","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T15:12:13Z","timestamp":1676473933000},"page":"181-209","source":"Crossref","is-referenced-by-count":515,"title":["Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"21","author":[{"given":"Nadeem","family":"Abu-Rustum","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catheryn","family":"Yashar","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Arend","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Barber","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Bradley","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Brooks","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana M.","family":"Campos","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center | Massachusetts General Hospital Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Chino","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sook","family":"Chon","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chu","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Ann","family":"Crispens","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Damast","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Fisher","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Frederick","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Gaffney","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Giuntoli","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Han","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Holmes","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke E.","family":"Howitt","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanthi","family":"Lea","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mariani","sequence":"additional","affiliation":[{"name":"Mayo Clinic Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mutch","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Nagel","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Nekhlyudov","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center | Massachusetts General Hospital Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna","family":"Podoll","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Salani","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Schorge","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Siedel","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sisodia","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center | Massachusetts General Hospital Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Soliman","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Ueda","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Urban","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Wethington","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Wyse","sequence":"additional","affiliation":[{"name":"Patient advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Zanotti","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"McMillian","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaili","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel RL","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE,  Cancer statistics, 2022. CA Cancer J Clin 2022;72:7\u201333.10.3322\/caac.21708"},{"key":"B2","series-title":"CA Cancer J Clin","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel RL","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7\u201330.10.3322\/caac.21332"},{"key":"B3","series-title":"Best Pract Res Clin Obstet Gynaecol","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bpobgyn.2011.08.002","article-title":"Screening for uterine tumours","volume":"26","author":"Van den Bosch T","year":"2012","unstructured":"Van den Bosch T, Coosemans A, Morina M,  Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol 2012;26:257\u2013266.10.1016\/j.bpobgyn.2011.08.002"},{"key":"B4","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/IGC.0b013e3181995f90","article-title":"Endometrial cancer state of the science meeting","volume":"19","author":"Kitchener HC","year":"2009","unstructured":"Kitchener HC, Trimble EL. Endometrial cancer state of the science meeting. Int J Gynecol Cancer 2009;19:134\u2013140.10.1111\/IGC.0b013e3181995f90"},{"key":"B5","series-title":"Obstet Gynecol Int","doi-asserted-by":"publisher","first-page":"583891","DOI":"10.1155\/2013\/583891","article-title":"Contemporary clinical management of endometrial cancer","volume":"2013","author":"Dinkelspiel HE","year":"2013","unstructured":"Dinkelspiel HE, Wright JD, Lewin SN,  Contemporary clinical management of endometrial cancer. Obstet Gynecol Int 2013;2013:583891.10.1155\/2013\/583891"},{"key":"B6","series-title":"Int J Cancer","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1002\/ijc.25501","article-title":"Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma","volume":"127","author":"Obermair A","year":"2010","unstructured":"Obermair A, Youlden DR, Young JP,  Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer 2010;127:2678\u20132684.10.1002\/ijc.25501"},{"key":"B7","series-title":"CA Cancer J Clin","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel RL","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7\u201330.10.3322\/caac.21387"},{"key":"B8","series-title":"Am J Obstet Gynecol","doi-asserted-by":"publisher","first-page":"218.E1","DOI":"10.1016\/j.ajog.2007.08.075","article-title":"Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths","volume":"198","author":"Ueda SM","year":"2008","unstructured":"Ueda SM, Kapp DS, Cheung MK,  Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008;198:218.E1\u2013E6.10.1016\/j.ajog.2007.08.075"},{"key":"B9","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1200\/JCO.2010.31.2124","article-title":"Influence of gynecologic oncologists on the survival of patients with endometrial cancer","volume":"29","author":"Chan JK","year":"2011","unstructured":"Chan JK, Sherman AE, Kapp DS,  Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol 2011;29:832\u2013838.10.1200\/JCO.2010.31.2124"},{"key":"B10","series-title":"Am J Obstet Gynecol","doi-asserted-by":"publisher","first-page":"363.E1","DOI":"10.1016\/j.ajog.2013.12.025","article-title":"Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma","volume":"210","author":"Benedetti Panici P","year":"2014","unstructured":"Benedetti Panici P, Basile S, Salerno MG,  Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 2014;210:363.E1\u2013E10.10.1016\/j.ajog.2013.12.025"},{"key":"B11","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ygyno.2013.10.023","article-title":"High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes","volume":"132","author":"Doll KM","year":"2014","unstructured":"Doll KM, Tseng J, Denslow SA,  High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes. Gynecol Oncol 2014;132:44\u201349.10.1016\/j.ygyno.2013.10.023"},{"key":"B12","series-title":"Front Oncol","doi-asserted-by":"publisher","first-page":"762329","DOI":"10.3389\/fonc.2021.762329","article-title":"Association of myometrial invasion with lymphovascular space invasion, lymph node metastasis, recurrence, and overall survival in endometrial cancer: a meta-analysis of 79 studies with 68,870 patients","volume":"11","author":"Wang J","year":"2021","unstructured":"Wang J, Xu P, Yang X,  Association of myometrial invasion with lymphovascular space invasion, lymph node metastasis, recurrence, and overall survival in endometrial cancer: a meta-analysis of 79 studies with 68,870 patients. Front Oncol 2021;11:762329.10.3389\/fonc.2021.762329"},{"key":"B13","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ygyno.2021.05.029","article-title":"Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma","volume":"162","author":"Raffone A","year":"2021","unstructured":"Raffone A, Travaglino A, Raimondo D,  Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma. Gynecol Oncol 2021;162:401\u2013406.10.1016\/j.ygyno.2021.05.029"},{"key":"B14","series-title":"Comprehensive Gynecology","article-title":"Diagnostic procedures. Imaging, endometrial sampling, endoscopy: indications and contraindications, complications","author":"Droegemueller W","year":"2007","unstructured":"Droegemueller W. Diagnostic procedures. Imaging, endometrial sampling, endoscopy: indications and contraindications, complications. In: Katz VL, Lentz GM, Lobo RA, , eds. Comprehensive Gynecology. 5th ed. Mosby; 2007."},{"key":"B15","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ygyno.2009.03.003","article-title":"Current and emerging trends in Lynch syndrome identification in women with endometrial cancer","volume":"114","author":"Resnick KE","year":"2009","unstructured":"Resnick KE, Hampel H, Fishel R,  Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol 2009;114:128\u2013134.10.1016\/j.ygyno.2009.03.003"},{"key":"B16","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/cncr.33516","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis","volume":"127","author":"McAlpine JN","year":"2021","unstructured":"McAlpine JN, Chiu DS, Nout RA,  Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis. Cancer 2021;127:2409\u20132422.10.1002\/cncr.33516"},{"key":"B17","series-title":"J Pathol Transl Med","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4132\/jptm.2020.07.23","article-title":"The frequency of POLE-mutation in endometrial carcinoma and prognostic implications: a systemic review and meta-analysis","volume":"54","author":"Jumaah AS","year":"2020","unstructured":"Jumaah AS, Salim MM, Al-Haddad HS,  The frequency of POLE-mutation in endometrial carcinoma and prognostic implications: a systemic review and meta-analysis. J Pathol Transl Med 2020;54:471\u2013479.10.4132\/jptm.2020.07.23"},{"key":"B18","series-title":"Arch Gynecol Obstet","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00404-020-05542-1","article-title":"Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups","volume":"301","author":"Travaglino A","year":"2020","unstructured":"Travaglino A, Raffone A, Stradella C,  Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups. Arch Gynecol Obstet 2020;301:1355\u20131363.10.1007\/s00404-020-05542-1"},{"key":"B19","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1200\/JCO.2010.32.9979","article-title":"Testing women with endometrial cancer to detect Lynch syndrome","volume":"29","author":"Kwon JS","year":"2011","unstructured":"Kwon JS, Scott JL, Gilks CB,  Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 2011;29:2247\u20132252.10.1200\/JCO.2010.32.9979"},{"key":"B20","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/JCO.2013.51.2129","article-title":"Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing","volume":"32","author":"Buchanan DD","year":"2014","unstructured":"Buchanan DD, Tan YY, Walsh MD,  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol 2014;32:90\u2013100.10.1200\/JCO.2013.51.2129"},{"key":"B21","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1002\/cncr.28933","article-title":"Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing","volume":"120","author":"Ferguson SE","year":"2014","unstructured":"Ferguson SE, Aronson M, Pollett A,  Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer 2014;120:3932\u20133939.10.1002\/cncr.28933"},{"key":"B22","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1200\/JCO.2015.63.9518","article-title":"Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for lynch syndrome screening in endometrial cancers from GOG210: an NRG oncology and Gynecologic Oncology Group study","volume":"33","author":"Goodfellow PJ","year":"2015","unstructured":"Goodfellow PJ, Billingsley CC, Lankes HA,  Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for lynch syndrome screening in endometrial cancers from GOG210: an NRG oncology and Gynecologic Oncology Group study. J Clin Oncol 2015;33:4301\u20134308.10.1200\/JCO.2015.63.9518"},{"key":"B23","series-title":"Int J Gynecol Pathol","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/PGP.0000000000000312","article-title":"Universal screening for mismatch- repair deficiency in endometrial cancers to identify patients with Lynch syndrome and Lynch-like syndrome","volume":"36","author":"Watkins JC","year":"2017","unstructured":"Watkins JC, Yang EJ, Muto MG,  Universal screening for mismatch- repair deficiency in endometrial cancers to identify patients with Lynch syndrome and Lynch-like syndrome. Int J Gynecol Pathol 2017;36:115\u2013127.10.1097\/PGP.0000000000000312"},{"key":"B24","series-title":"Am J Surg Pathol","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1097\/PAS.0000000000000321","article-title":"Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer","volume":"38","author":"Mills AM","year":"2014","unstructured":"Mills AM, Liou S, Ford JM,  Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol 2014;38:1501\u20131509.10.1097\/PAS.0000000000000321"},{"key":"B25","series-title":"Pathol Oncol Res","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s12253-020-00811-5","article-title":"Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer","volume":"26","author":"Raffone A","year":"2020","unstructured":"Raffone A, Travaglino A, Cerbone M,  Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer. Pathol Oncol Res 2020;26:1417\u20131427.10.1007\/s12253-020-00811-5"},{"key":"B26","series-title":"Dig Liver Dis","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.dld.2011.12.020","article-title":"Simplified identification of Lynch syndrome: a prospective, multicenter study","volume":"44","author":"Bonnet D","year":"2012","unstructured":"Bonnet D, Selves J, Toulas C,  Simplified identification of Lynch syndrome: a prospective, multicenter study. Dig Liver Dis 2012;44:515\u2013522.10.1016\/j.dld.2011.12.020"},{"key":"B27","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/jnci\/djs525","article-title":"Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome","volume":"105","author":"Win AK","year":"2013","unstructured":"Win AK, Lindor NM, Winship I,  Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst 2013;105:274\u2013279.10.1093\/jnci\/djs525"},{"key":"B28","series-title":"Arch Gynecol Obstet","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00404-012-2492-2","article-title":"Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC\/Lynch syndrome (LS)","volume":"286","author":"Manchanda R","year":"2012","unstructured":"Manchanda R, Saridogan E, Abdelraheim A,  Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC\/Lynch syndrome (LS). Arch Gynecol Obstet 2012;286:1555\u20131562.10.1007\/s00404-012-2492-2"},{"key":"B29","series-title":"Cancer Control","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/107327480901600103","article-title":"Endometrial cancer and Lynch syndrome: clinical and pathologic considerations","volume":"16","author":"Meyer LA","year":"2009","unstructured":"Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009;16:14\u201322.10.1177\/107327480901600103"},{"key":"B30","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1200\/JCO.2009.23.7784","article-title":"Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members","volume":"27","author":"J\u00e4rvinen HJ","year":"2009","unstructured":"J\u00e4rvinen HJ, Renkonen-Sinisalo L, Akt\u00e1n-Coll\u00e1n K,  Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009;27:4793\u20134797.10.1200\/JCO.2009.23.7784"},{"key":"B31","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1056\/NEJMoa052627","article-title":"Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome","volume":"354","author":"Schmeler KM","year":"2006","unstructured":"Schmeler KM, Lynch HT, Chen LM,  Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261\u2013269.10.1056\/NEJMoa052627"},{"key":"B32","series-title":"Obstet Gynecol Clin North Am","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ogc.2012.04.001","article-title":"Endometrial cancer","volume":"39","author":"Leslie KK","year":"2012","unstructured":"Leslie KK, Thiel KW, Goodheart MJ,  Endometrial cancer. Obstet Gynecol Clin North Am 2012;39:255\u2013268.10.1016\/j.ogc.2012.04.001"},{"key":"B33","series-title":"CA Cancer J Clin","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3322\/caac.21174","article-title":"Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening","volume":"63","author":"Smith RA","year":"2013","unstructured":"Smith RA, Brooks D, Cokkinides V,  Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 2013;63:88\u2013105.10.3322\/caac.21174"},{"key":"B34","series-title":"J Clin Pathol","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1136\/jcp.2005.029702","article-title":"My approach to the interpretation of endometrial biopsies and curettings","volume":"59","author":"McCluggage WG","year":"2006","unstructured":"McCluggage WG. My approach to the interpretation of endometrial biopsies and curettings. J Clin Pathol 2006;59:801\u2013812.10.1136\/jcp.2005.029702"},{"key":"B35","series-title":"Adv Anat Pathol","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PAP.0b013e3181919e15","article-title":"Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics","volume":"16","author":"McKenney JK","year":"2009","unstructured":"McKenney JK, Longacre TA. Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics. Adv Anat Pathol 2009;16:1\u201322.10.1097\/PAP.0b013e3181919e15"},{"key":"B36","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ygyno.2008.12.017","article-title":"Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma","volume":"113","author":"Leitao MM Jr","year":"2009","unstructured":"Leitao MM Jr, Kehoe S, Barakat RR,  Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2009;113:105\u2013108.10.1016\/j.ygyno.2008.12.017"},{"key":"B37","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ygyno.2013.05.011","article-title":"Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET\/CT","volume":"130","author":"Crivellaro C","year":"2013","unstructured":"Crivellaro C, Signorelli M, Guerra L,  Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET\/CT. Gynecol Oncol 2013;130:306\u2013311.10.1016\/j.ygyno.2013.05.011"},{"key":"B38","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ygyno.2012.11.025","article-title":"MRI, PET\/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study","volume":"128","author":"Antonsen SL","year":"2013","unstructured":"Antonsen SL, Jensen LN, Loft A,  MRI, PET\/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study. Gynecol Oncol 2013;128:300\u2013308.10.1016\/j.ygyno.2012.11.025"},{"key":"B39","series-title":"J Nucl Med","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2967\/jnumed.115.170597","article-title":"High diagnostic value of 18F-FDG PET\/CT in endometrial cancer: systematic review and meta-analysis of the literature","volume":"57","author":"Bollineni VR","year":"2016","unstructured":"Bollineni VR, Ytre-Hauge S, Bollineni-Balabay O,  High diagnostic value of 18F-FDG PET\/CT in endometrial cancer: systematic review and meta-analysis of the literature. J Nucl Med 2016;57:879\u2013885.10.2967\/jnumed.115.170597"},{"key":"B40","series-title":"J Am Coll Radiol","doi-asserted-by":"publisher","first-page":"S472","DOI":"10.1016\/j.jacr.2020.09.001","article-title":"ACR Appropriateness Criteria pretreatment evaluation and follow-up of endometrial cancer","volume":"17","author":"Reinhold C","year":"2020","unstructured":"Reinhold C, Ueno Y, Akin EA,  ACR Appropriateness Criteria pretreatment evaluation and follow-up of endometrial cancer. J Am Coll Radiol 2020;17(Suppl 11):S472\u2013486.10.1016\/j.jacr.2020.09.001"},{"key":"B41","series-title":"Am J Obstet Gynecol","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/0002-9378(90)90400-2","article-title":"Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma","volume":"162","author":"Patsner B","year":"1990","unstructured":"Patsner B, Orr JW Jr, Mann WJ Jr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol 1990;162:427\u2013429.10.1016\/0002-9378(90)90400-2"},{"key":"B42","series-title":"Obstet Gynecol","first-page":"12","article-title":"Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma","volume":"84","author":"Rose PG","year":"1994","unstructured":"Rose PG, Sommers RM, Reale FR,  Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol 1994;84:12\u201316."},{"key":"B43","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8","article-title":"Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study","volume":"60","author":"Creasman WT","year":"1987","unstructured":"Creasman WT, Morrow CP, Bundy BN,  Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60(Suppl 8):2035\u20132041.10.1002\/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8"},{"key":"B44","series-title":"Int J Gynaecol Obstet","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers","volume":"70","author":"Benedet JL","year":"2000","unstructured":"Benedet JL, Bender H, Jones H III,  FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 2000;70:209\u2013262.10.1016\/S0020-7292(00)90001-8"},{"key":"B45","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(12)60442-5","article-title":"Contemporary management of endometrial cancer","volume":"379","author":"Wright JD","year":"2012","unstructured":"Wright JD, Barrena Medel NI, Sehouli J,  Contemporary management of endometrial cancer. Lancet 2012;379:1352\u20131360.10.1016\/S0140-6736(12)60442-5"},{"key":"B46","series-title":"Int J Gynaecol Obstet","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijgo.2009.02.010","article-title":"Revised FIGO staging for carcinoma of the endometrium","volume":"105","author":"Creasman W","year":"2009","unstructured":"Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 2009;105:109.10.1016\/j.ijgo.2009.02.010"},{"key":"B47","series-title":"Int J Gynaecol Obstet","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijgo.2009.02.008","article-title":"New surgical staging of endometrial cancer: 20 years later","volume":"105","author":"Mariani A","year":"2009","unstructured":"Mariani A, Dowdy SC, Podratz KC. New surgical staging of endometrial cancer: 20 years later. Int J Gynaecol Obstet 2009;105:110\u2013111.10.1016\/j.ijgo.2009.02.008"},{"key":"B48","series-title":"AJCC Cancer Staging Manual","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40618-3","author":"Amin MB","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL,  AJCC Cancer Staging Manual. 8th ed. Springer; 2017.10.1007\/978-3-319-40618-3"},{"key":"B49","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ygyno.2018.02.012","article-title":"Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer","volume":"149","author":"Matsuo K","year":"2018","unstructured":"Matsuo K, Yabuno A, Hom MS,  Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer. Gynecol Oncol 2018;149:301\u2013309.10.1016\/j.ygyno.2018.02.012"},{"key":"B50","series-title":"Int J Gynecol Pathol","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/PGP.0000000000000806","article-title":"Defining substantial lymphovascular space invasion in endometrial cancer","volume":"41","author":"Peters EEM","year":"2022","unstructured":"Peters EEM, Le\u00f3n-Castillo A, Smit VT,  Defining substantial lymphovascular space invasion in endometrial cancer. Int J Gynecol Pathol 2022;41:220\u2013226.10.1097\/PGP.0000000000000806"},{"key":"B51","series-title":"TNM Classification of Malignant Tumours","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. John Wiley & Sons; 2017."},{"key":"B52","series-title":"Mod Pathol","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann D","year":"2020","unstructured":"Rottmann D, Snir OL, Wu X,  HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Mod Pathol 2020;33:118\u2013127.10.1038\/s41379-019-0358-x"},{"key":"B53","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/ijgc-2019-000920","article-title":"Molecular variations in uterine carcinosarcomas identify therapeutic opportunities","volume":"30","author":"Crane E","year":"2020","unstructured":"Crane E, Naumann W, Tait D,  Molecular variations in uterine carcinosarcomas identify therapeutic opportunities. Int J Gynecol Cancer 2020;30:480\u2013484.10.1136\/ijgc-2019-000920"},{"key":"B54","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ygyno.2005.07.124","article-title":"EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma","volume":"100","author":"Livasy CA","year":"2006","unstructured":"Livasy CA, Reading FC, Moore DT,  EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma. Gynecol Oncol 2006;100:101\u2013106.10.1016\/j.ygyno.2005.07.124"},{"key":"B55","series-title":"Virchows Arch","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00428-021-03017-5","article-title":"Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy","volume":"478","author":"Yoshida H","year":"2021","unstructured":"Yoshida H, Nishikawa T, Matsumoto K,  Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. Virchows Arch 2021;478:1161\u20131171.10.1007\/s00428-021-03017-5"},{"key":"B56","series-title":"Am J Surg Pathol","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/PAS.0000000000001870","article-title":"HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology","volume":"46","author":"Jenkins TM","year":"2022","unstructured":"Jenkins TM, Cantrell LA, Stoler MH,  HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology. Am J Surg Pathol 2022;46:435\u2013442.10.1097\/PAS.0000000000001870"},{"key":"B57","series-title":"Int J Gynecol Pathol","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/01.pgp.0000233165.56385.0b","article-title":"Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma","volume":"26","author":"Ali A","year":"2007","unstructured":"Ali A, Black D, Soslow RA. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 2007;26:115\u2013123.10.1097\/01.pgp.0000233165.56385.0b"},{"key":"B58","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/0090-8258(90)90009-A","article-title":"Assessment of depth of myometrial invasion in endometrial adenocarcinoma","volume":"38","author":"Goff BA","year":"1990","unstructured":"Goff BA, Rice LW. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 1990;38:46\u201348.10.1016\/0090-8258(90)90009-A"},{"key":"B59","series-title":"Obstet Gynecol","first-page":"612","article-title":"Accuracy of office and operating room curettage in the grading of endometrial carcinoma","volume":"71","author":"Daniel AG","year":"1988","unstructured":"Daniel AG, Peters WA III. Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol 1988;71:612\u2013614."},{"key":"B60","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ygyno.2010.07.011","article-title":"Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists","volume":"119","author":"Soliman PT","year":"2010","unstructured":"Soliman PT, Frumovitz M, Spannuth W,  Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol 2010;119:291\u2013294.10.1016\/j.ygyno.2010.07.011"},{"key":"B61","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ygyno.2013.05.035","article-title":"Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer","volume":"130","author":"Kumar S","year":"2013","unstructured":"Kumar S, Mariani A, Bakkum-Gamez JN,  Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. Gynecol Oncol 2013;130:441\u2013445.10.1016\/j.ygyno.2013.05.035"},{"key":"B62","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S0140-6736(09)62002-X","article-title":"Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis","volume":"375","author":"Todo Y","year":"2010","unstructured":"Todo Y, Kato H, Kaneuchi M,  Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010;375:1165\u20131172.10.1016\/S0140-6736(09)62002-X"},{"key":"B63","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","article-title":"Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study","volume":"373","author":"Kitchener H","year":"2009","unstructured":"Kitchener H, Swart AM, Qian Q,  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125\u2013136.10.1016\/S0140-6736(08)61766-3"},{"key":"B64","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/jnci\/djn397","article-title":"Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial","volume":"100","author":"Benedetti Panici P","year":"2008","unstructured":"Benedetti Panici P, Basile S, Maneschi F,  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707\u20131716.10.1093\/jnci\/djn397"},{"key":"B65","series-title":"Obstet Gynecol","first-page":"413","article-title":"ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer","volume":"106","year":"2005","unstructured":"American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005;106:413\u2013425."},{"key":"B66","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ygyno.2009.12.025","article-title":"Lymphadenectomy for endometrial cancer: the controversy","volume":"117","author":"Seamon LG","year":"2010","unstructured":"Seamon LG, Fowler JM, Cohn DE. Lymphadenectomy for endometrial cancer: the controversy. Gynecol Oncol 2010;117:6\u20138.10.1016\/j.ygyno.2009.12.025"},{"key":"B67","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2009.10.065","article-title":"ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid?","volume":"116","author":"Creasman WT","year":"2010","unstructured":"Creasman WT, Mutch DE, Herzog TJ. ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid? Gynecol Oncol 2010;116:293\u2013294.10.1016\/j.ygyno.2009.10.065"},{"key":"B68","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/S0140-6736(09)60677-2","article-title":"Lymphadenectomy in endometrial cancer","volume":"373","author":"Uccella S","year":"2009","unstructured":"Uccella S, Podratz KC, Aletti GD,  Lymphadenectomy in endometrial cancer. Lancet 2009;373:1170; author reply 1170\u20131171.10.1016\/S0140-6736(09)60677-2"},{"key":"B69","series-title":"Obstet Gynecol","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/AOG.0b013e318240de51","article-title":"Nodal metastasis risk in endometrioid endometrial cancer","volume":"119","author":"Milam MR","year":"2012","unstructured":"Milam MR, Java J, Walker JL,  Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol 2012;119:286\u2013292.10.1097\/AOG.0b013e318240de51"},{"key":"B70","series-title":"Int J Surg Oncol","first-page":"814649","article-title":"The role of lymphadenectomy in surgical staging of endometrial cancer","volume":"2011","author":"Neubauer NL","year":"2011","unstructured":"Neubauer NL, Lurain JR. The role of lymphadenectomy in surgical staging of endometrial cancer. Int J Surg Oncol 2011;2011:814649."},{"key":"B71","series-title":"Am J Obstet Gynecol","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ajog.2016.11.1033","article-title":"Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis","volume":"216","author":"Bodurtha Smith AJ","year":"2017","unstructured":"Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol 2017;216:459\u2013476.e10.10.1016\/j.ajog.2016.11.1033"},{"key":"B72","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ygyno.2008.01.023","article-title":"Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging","volume":"109","author":"Mariani A","year":"2008","unstructured":"Mariani A, Dowdy SC, Cliby WA,  Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008;109:11\u201318.10.1016\/j.ygyno.2008.01.023"},{"key":"B73","series-title":"J Surg Oncol","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/(SICI)1096-9098(199706)65:2<82::AID-JSO3>3.0.CO;2-J","article-title":"A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma","volume":"65","author":"Hirahatake K","year":"1997","unstructured":"Hirahatake K, Hareyama H, Sakuragi N,  A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. J Surg Oncol 1997;65:82\u201387.10.1002\/(SICI)1096-9098(199706)65:2<82::AID-JSO3>3.0.CO;2-J"},{"key":"B74","series-title":"Cancer Contr","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/107327480901600104","article-title":"The role of comprehensive surgical staging in patients with endometrial cancer","volume":"16","author":"Frederick PJ","year":"2009","unstructured":"Frederick PJ, Straughn JM Jr. The role of comprehensive surgical staging in patients with endometrial cancer. Cancer Contr 2009;16:23\u201329.10.1177\/107327480901600104"},{"key":"B75","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ygyno.2012.02.021","article-title":"The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes","volume":"125","author":"Barlin JN","year":"2012","unstructured":"Barlin JN, Khoury-Collado F, Kim CH,  The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 2012;125:531\u2013535.10.1016\/j.ygyno.2012.02.021"},{"key":"B76","series-title":"BMC Cancer","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/1471-2407-10-465","article-title":"Does the use of the 2009 FIGO classification of endometrial cancer impact on indications of the sentinel node biopsy?","volume":"10","author":"Ballester M","year":"2010","unstructured":"Ballester M, Koskas M, Coutant C,  Does the use of the 2009 FIGO classification of endometrial cancer impact on indications of the sentinel node biopsy? BMC Cancer 2010;10:465.10.1186\/1471-2407-10-465"},{"key":"B77","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ygyno.2012.08.018","article-title":"Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: a prospective study","volume":"127","author":"How J","year":"2012","unstructured":"How J, Lau S, Press J,  Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: a prospective study. Gynecol Oncol 2012;127:332\u2013337.10.1016\/j.ygyno.2012.08.018"},{"key":"B78","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ygyno.2011.04.030","article-title":"Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes","volume":"122","author":"Khoury-Collado F","year":"2011","unstructured":"Khoury-Collado F, Murray MP, Hensley ML,  Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. Gynecol Oncol 2011;122:251\u2013254.10.1016\/j.ygyno.2011.04.030"},{"key":"B79","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ygyno.2017.05.027","article-title":"Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations","volume":"146","author":"Holloway RW","year":"2017","unstructured":"Holloway RW, Abu-Rustum NR, Backes FJ,  Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol 2017;146:405\u2013415.10.1016\/j.ygyno.2017.05.027"},{"key":"B80","series-title":"Oncologist","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1634\/theoncologist.2015-0473","article-title":"Sentinel lymph node mapping in endometrial cancer: an update","volume":"21","author":"Khoury-Collado F","year":"2016","unstructured":"Khoury-Collado F, St Clair C, Abu-Rustum NR. Sentinel lymph node mapping in endometrial cancer: an update. Oncologist 2016;21:461\u2013466.10.1634\/theoncologist.2015-0473"},{"key":"B81","series-title":"Lancet Oncol","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study","volume":"18","author":"Rossi EC","year":"2017","unstructured":"Rossi EC, Kowalski LD, Scalici J,  A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 2017;18:384\u2013392.10.1016\/S1470-2045(17)30068-2"},{"key":"B82","series-title":"Am J Obstet Gynecol","doi-asserted-by":"publisher","first-page":"117.E1","DOI":"10.1016\/j.ajog.2015.12.046","article-title":"A prospective investigation of fluorescence imaging to detect sentinel lymph nodes at robotic-assisted endometrial cancer staging","volume":"215","author":"Paley PJ","year":"2016","unstructured":"Paley PJ, Veljovich DS, Press JZ,  A prospective investigation of fluorescence imaging to detect sentinel lymph nodes at robotic-assisted endometrial cancer staging. Am J Obstet Gynecol 2016;215:117.E1\u2013E7.10.1016\/j.ajog.2015.12.046"},{"key":"B83","series-title":"Ann Surg Oncol","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1245\/s10434-016-5236-x","article-title":"Sentinel node mapping in cervical and endometrial cancer: indocyanine green versus other conventional dyes-a meta-analysis","volume":"23","author":"Ruscito I","year":"2016","unstructured":"Ruscito I, Gasparri ML, Braicu EI,  Sentinel node mapping in cervical and endometrial cancer: indocyanine green versus other conventional dyes-a meta-analysis. Ann Surg Oncol 2016;23:3749\u20133756.10.1245\/s10434-016-5236-x"},{"key":"B84","series-title":"Lancet Oncol","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/S1470-2045(18)30448-0","article-title":"Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial","volume":"19","author":"Frumovitz M","year":"2018","unstructured":"Frumovitz M, Plante M, Lee PS,  Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Lancet Oncol 2018;19:1394\u20131403.10.1016\/S1470-2045(18)30448-0"},{"key":"B85","series-title":"Eur J Obstet Gynecol Reprod Biol","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejogrb.2021.04.015","article-title":"Maximizing sentinel node detection in endometrial cancer with dual cervical and transcervical fundal indocyanine green injection: 5-year single-center prospective study","volume":"261","author":"Ruiz R","year":"2021","unstructured":"Ruiz R, Gorostidi M, Jaunarena I,  Maximizing sentinel node detection in endometrial cancer with dual cervical and transcervical fundal indocyanine green injection: 5-year single-center prospective study. Eur J Obstet Gynecol Reprod Biol 2021;261:59\u201364.10.1016\/j.ejogrb.2021.04.015"},{"key":"B86","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ygyno.2019.03.252","article-title":"Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739)","volume":"153","author":"Backes FJ","year":"2019","unstructured":"Backes FJ, Cohen D, Salani R,  Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). Gynecol Oncol 2019;153:496\u2013499.10.1016\/j.ygyno.2019.03.252"},{"key":"B87","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/IGC.0b013e31829b1b98","article-title":"Evaluation of the sentinel lymph node algorithm with blue dye labeling for early-stage endometrial cancer in a multicentric setting","volume":"23","author":"Vidal F","year":"2013","unstructured":"Vidal F, Leguevaque P, Motton S,  Evaluation of the sentinel lymph node algorithm with blue dye labeling for early-stage endometrial cancer in a multicentric setting. Int J Gynecol Cancer 2013;23:1237\u20131243.10.1097\/IGC.0b013e31829b1b98"},{"key":"B88","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ygyno.2009.01.003","article-title":"Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?","volume":"113","author":"Abu-Rustum NR","year":"2009","unstructured":"Abu-Rustum NR, Khoury-Collado F, Pandit-Taskar N,  Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol 2009;113:163\u2013169.10.1016\/j.ygyno.2009.01.003"},{"key":"B89","series-title":"Lancet Oncol","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S1470-2045(11)70070-5","article-title":"Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO)","volume":"12","author":"Ballester M","year":"2011","unstructured":"Ballester M, Dubernard G, L\u00e9curu F,  Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 2011;12:469\u2013476.10.1016\/S1470-2045(11)70070-5"},{"key":"B90","series-title":"Obstet Gynecol Int","doi-asserted-by":"publisher","first-page":"578490","DOI":"10.1155\/2012\/578490","article-title":"Controversies in the treatment of early stage endometrial carcinoma","volume":"2012","author":"Press JZ","year":"2012","unstructured":"Press JZ, Gotlieb WH. Controversies in the treatment of early stage endometrial carcinoma. Obstet Gynecol Int 2012;2012:578490.10.1155\/2012\/578490"},{"key":"B91","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ygyno.2015.04.008","article-title":"Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer","volume":"138","author":"Touhami O","year":"2015","unstructured":"Touhami O, Trinh XB, Gregoire J,  Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecol Oncol 2015;138:41\u201345.10.1016\/j.ygyno.2015.04.008"},{"key":"B92","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ygyno.2014.05.018","article-title":"Endometrial cancer: a review and current management strategies: part I","volume":"134","author":"Burke WM","year":"2014","unstructured":"Burke WM, Orr J, Leitao M,  Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol 2014;134:385\u2013392.10.1016\/j.ygyno.2014.05.018"},{"key":"B93","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ygyno.2017.05.016","article-title":"A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer","volume":"146","author":"Soliman PT","year":"2017","unstructured":"Soliman PT, Westin SN, Dioun S,  A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol 2017;146:234\u2013239.10.1016\/j.ygyno.2017.05.016"},{"key":"B94","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ygyno.2013.09.027","article-title":"Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion","volume":"131","author":"Kim CH","year":"2013","unstructured":"Kim CH, Khoury-Collado F, Barber EL,  Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol 2013;131:714\u2013719.10.1016\/j.ygyno.2013.09.027"},{"key":"B95","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ygyno.2015.05.039","article-title":"Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research","volume":"138","author":"Cormier B","year":"2015","unstructured":"Cormier B, Rozenholc AT, Gotlieb W,  Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research. Gynecol Oncol 2015;138:478\u2013485.10.1016\/j.ygyno.2015.05.039"},{"key":"B96","series-title":"Gynecol Oncol","first-page":"206","article-title":"Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis","volume":"141","author":"Holloway RW","year":"2016","unstructured":"Holloway RW, Gupta S, Stavitzski NM,  Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. Gynecol Oncol 2016;141:206\u2013210."},{"key":"B97","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ygyno.2014.09.011","article-title":"Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study","volume":"136","author":"Dara\u00ef E","year":"2015","unstructured":"Dara\u00ef E, Dubernard G, Bats AS,  Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol Oncol 2015;136:54\u201359.10.1016\/j.ygyno.2014.09.011"},{"key":"B98","series-title":"Ultrasound Q","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/RUQ.0b013e31821b6f73","article-title":"ACR Appropriateness Criteria pretreatment evaluation and follow-up of endometrial cancer of the uterus","volume":"27","author":"Lee JH","year":"2011","unstructured":"Lee JH, Dubinsky T, Andreotti RF,  ACR Appropriateness Criteria pretreatment evaluation and follow-up of endometrial cancer of the uterus. Ultrasound Q 2011;27:139\u2013145.10.1097\/RUQ.0b013e31821b6f73"},{"key":"B99","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ygyno.2014.10.027","article-title":"Relevance of sentinel lymph node procedure for patients with high-risk endometrial cancer","volume":"136","author":"Naoura I","year":"2015","unstructured":"Naoura I, Canlorbe G, Bendifallah S,  Relevance of sentinel lymph node procedure for patients with high-risk endometrial cancer. Gynecol Oncol 2015;136:60\u201364.10.1016\/j.ygyno.2014.10.027"},{"key":"B100","series-title":"Ann Surg Oncol","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1245\/s10434-015-4612-2","article-title":"Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping","volume":"23","author":"Schiavone MB","year":"2016","unstructured":"Schiavone MB, Zivanovic O, Zhou Q,  Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping. Ann Surg Oncol 2016;23:196\u2013202.10.1245\/s10434-015-4612-2"},{"key":"B101","series-title":"J Clin Med","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.3390\/jcm9123874","article-title":"Diagnostic accuracy and clinical impact of sentinel lymph node sampling in endometrial cancer at high risk of recurrence: a meta-analysis","volume":"9","author":"Lecointre L","year":"2020","unstructured":"Lecointre L, Lodi M, Faller \u00c9,  Diagnostic accuracy and clinical impact of sentinel lymph node sampling in endometrial cancer at high risk of recurrence: a meta-analysis. J Clin Med 2020;9:3874.10.3390\/jcm9123874"},{"key":"B102","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ygyno.2021.01.008","article-title":"Sentinel node mapping vs sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: results from a multi-institutional study","volume":"161","author":"Bogani G","year":"2021","unstructured":"Bogani G, Papadia A, Buda A,  Sentinel node mapping vs sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: results from a multi-institutional study. Gynecol Oncol 2021;161:122\u2013129.10.1016\/j.ygyno.2021.01.008"},{"key":"B103","series-title":"JAMA Surg","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/jamasurg.2020.5060","article-title":"Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging","volume":"156","author":"Cusimano MC","year":"2021","unstructured":"Cusimano MC, Vicus D, Pulman K,  Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging. JAMA Surg 2021;156:157\u2013164.10.1001\/jamasurg.2020.5060"},{"key":"B104","series-title":"Am J Obstet Gynecol","doi-asserted-by":"publisher","first-page":"367.E1","DOI":"10.1016\/j.ajog.2021.05.034","article-title":"Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics","volume":"225","author":"Marchocki Z","year":"2021","unstructured":"Marchocki Z, Cusimano MC, Clarfield L,  Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol 2021;225:367.E1\u2013E39.10.1016\/j.ajog.2021.05.034"},{"key":"B105","series-title":"Int J Gynecol Pathol","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/PGP.0000000000000415","article-title":"Ultrastaging of sentinel lymph nodes in endometrial carcinoma according to use of 2 different methods","volume":"37","author":"Euscher E","year":"2018","unstructured":"Euscher E, Sui D, Soliman P,  Ultrastaging of sentinel lymph nodes in endometrial carcinoma according to use of 2 different methods. Int J Gynecol Pathol 2018;37:242\u2013251.10.1097\/PGP.0000000000000415"},{"key":"B106","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/ijgc-2020-001964","article-title":"Ultrastaging methods of sentinel lymph nodes in endometrial cancer - a systematic review","volume":"31","author":"Burg LC","year":"2021","unstructured":"Burg LC, Hengeveld EM, in \u2018t Hout J,  Ultrastaging methods of sentinel lymph nodes in endometrial cancer - a systematic review. Int J Gynecol Cancer 2021;31:744\u2013753.10.1136\/ijgc-2020-001964"},{"key":"B107","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/IGC.0b013e3182954da8","article-title":"Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging","volume":"23","author":"Kim CH","year":"2013","unstructured":"Kim CH, Soslow RA, Park KJ,  Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer 2013;23:964\u2013970.10.1097\/IGC.0b013e3182954da8"},{"key":"B108","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ygyno.2014.03.019","article-title":"Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: results of a retrospective multicenter study","volume":"133","author":"Raimond E","year":"2014","unstructured":"Raimond E, Ballester M, Hudry D,  Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: results of a retrospective multicenter study. Gynecol Oncol 2014;133:506\u2013511.10.1016\/j.ygyno.2014.03.019"},{"key":"B109","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1136\/ijgc-00009577-200605000-00058","article-title":"Endometrial cancer patients have a significant risk of harboring isolated tumor cells in histologically negative lymph nodes","volume":"16","author":"Amezcua CA","year":"2006","unstructured":"Amezcua CA, MacDonald HR, Lum CA,  Endometrial cancer patients have a significant risk of harboring isolated tumor cells in histologically negative lymph nodes. Int J Gynecol Cancer 2006;16:1336\u20131341.10.1136\/ijgc-00009577-200605000-00058"},{"key":"B110","series-title":"J Gynecol Oncol","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3802\/jgo.2016.27.e1","article-title":"Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer","volume":"27","author":"Todo Y","year":"2016","unstructured":"Todo Y, Kato H, Okamoto K,  Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer. J Gynecol Oncol 2016;27:e1.10.3802\/jgo.2016.27.e1"},{"key":"B111","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ygyno.2010.08.030","article-title":"Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artifact of uterine manipulation?","volume":"119","author":"Frimer M","year":"2010","unstructured":"Frimer M, Khoury-Collado F, Murray MP,  Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artifact of uterine manipulation? Gynecol Oncol 2010;119:496\u2013499.10.1016\/j.ygyno.2010.08.030"},{"key":"B112","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","article-title":"Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500","volume":"32","author":"Smerage JB","year":"2014","unstructured":"Smerage JB, Barlow WE, Hortobagyi GN,  Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014;32:3483\u20133489.10.1200\/JCO.2014.56.2561"},{"key":"B113","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ygyno.2018.02.021","article-title":"Lymphnode staging update in the American Joint Committee on Cancer 8th edition cancer staging manual","volume":"150","author":"Olawaiye AB","year":"2018","unstructured":"Olawaiye AB, Mutch DG. Lymphnode staging update in the American Joint Committee on Cancer 8th edition cancer staging manual. Gynecol Oncol 2018;150:7\u20138.10.1016\/j.ygyno.2018.02.021"},{"key":"B114","series-title":"Ann Surg Oncol","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1245\/s10434-015-5040-z","article-title":"Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma","volume":"23","author":"St Clair CM","year":"2016","unstructured":"St Clair CM, Eriksson AG, Ducie JA,  Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. Ann Surg Oncol 2016;23:1653\u20131659.10.1245\/s10434-015-5040-z"},{"key":"B115","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ygyno.2017.05.024","article-title":"Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: does adjuvant treatment matter?","volume":"146","author":"Plante M","year":"2017","unstructured":"Plante M, Stanleigh J, Renaud MC,  Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: does adjuvant treatment matter? Gynecol Oncol 2017;146:240\u2013246.10.1016\/j.ygyno.2017.05.024"},{"key":"B116","series-title":"Clin Transl Oncol","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1007\/s12094-019-02249-x","article-title":"Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis","volume":"22","author":"G\u00f3mez-Hidalgo NR","year":"2020","unstructured":"G\u00f3mez-Hidalgo NR, Ramirez PT, Ngo B,  Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis. Clin Transl Oncol 2020;22:1272\u20131279.10.1007\/s12094-019-02249-x"},{"key":"B117","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ygyno.2014.11.014","article-title":"The trend towards minimally invasive surgery (MIS) for endometrial cancer: an ACS-NSQIP evaluation of surgical outcomes","volume":"136","author":"Scalici J","year":"2015","unstructured":"Scalici J, Laughlin BB, Finan MA,  The trend towards minimally invasive surgery (MIS) for endometrial cancer: an ACS-NSQIP evaluation of surgical outcomes. Gynecol Oncol 2015;136:512\u2013515.10.1016\/j.ygyno.2014.11.014"},{"key":"B118","series-title":"JAMA","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1001\/jama.2017.2068","article-title":"Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial","volume":"317","author":"Janda M","year":"2017","unstructured":"Janda M, Gebski V, Davies LC,  Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA 2017;317:1224\u20131233.10.1001\/jama.2017.2068"},{"key":"B119","series-title":"Obstet Gynecol","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/AOG.0000000000001180","article-title":"Utilization of minimally invasive surgery in endometrial cancer care: a quality and cost disparity","volume":"127","author":"Fader AN","year":"2016","unstructured":"Fader AN, Weise RM, Sinno AK,  Utilization of minimally invasive surgery in endometrial cancer care: a quality and cost disparity. Obstet Gynecol 2016;127:91\u2013100.10.1097\/AOG.0000000000001180"},{"key":"B120","series-title":"Cochrane Database Syst Rev","first-page":"CD006655","article-title":"Laparoscopy versus laparotomy for the management of early stage endometrial cancer","volume":"9","author":"Galaal K","year":"2012","unstructured":"Galaal K, Bryant A, Fisher AD,  Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2012;9:CD006655."},{"key":"B121","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1200\/JCO.2009.22.3529","article-title":"Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study","volume":"27","author":"Kornblith AB","year":"2009","unstructured":"Kornblith AB, Huang HQ, Walker JL,  Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:5337\u20135342.10.1200\/JCO.2009.22.3529"},{"key":"B122","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1200\/JCO.2009.22.3248","article-title":"Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group study LAP2","volume":"27","author":"Walker JL","year":"2009","unstructured":"Walker JL, Piedmonte MR, Spirtos NM,  Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group study LAP2. J Clin Oncol 2009;27:5331\u20135336.10.1200\/JCO.2009.22.3248"},{"key":"B123","series-title":"Obstet Gynecol","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/AOG.0000000000001567","article-title":"Disparities in surgical care among women with endometrial cancer","volume":"128","author":"Mannschreck D","year":"2016","unstructured":"Mannschreck D, Matsuno RK, Moriarty JP,  Disparities in surgical care among women with endometrial cancer. Obstet Gynecol 2016;128:526\u2013534.10.1097\/AOG.0000000000001567"},{"key":"B124","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1200\/JCO.2011.38.8645","article-title":"Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study","volume":"30","author":"Walker JL","year":"2012","unstructured":"Walker JL, Piedmonte MR, Spirtos NM,  Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 2012;30:695\u2013700.10.1200\/JCO.2011.38.8645"},{"key":"B125","series-title":"Rev Recent Clin Trials","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2174\/157488709788186012","article-title":"Recent progress: gynecologic oncology group trials in uterine corpus tumors","volume":"4","author":"King LP","year":"2009","unstructured":"King LP, Miller DS. Recent progress: gynecologic oncology group trials in uterine corpus tumors. Rev Recent Clin Trials 2009;4:70\u201374.10.2174\/157488709788186012"},{"key":"B126","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1200\/JCO.2009.23.9822","article-title":"Is it safe to treat endometrial carcinoma endoscopically?","volume":"27","author":"Vergote I","year":"2009","unstructured":"Vergote I, Amant F, Neven P. Is it safe to treat endometrial carcinoma endoscopically? J Clin Oncol 2009;27:5305\u20135307.10.1200\/JCO.2009.23.9822"},{"key":"B127","series-title":"Lancet Oncol","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(10)70143-1","article-title":"Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial","volume":"11","author":"Mourits MJ","year":"2010","unstructured":"Mourits MJ, Bijen CB, Arts HJ,  Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol 2010;11:763\u2013771.10.1016\/S1470-2045(10)70143-1"},{"key":"B128","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ygyno.2021.12.019","article-title":"Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: long-term outcomes of a randomised trial","volume":"164","author":"Reijntjes B","year":"2022","unstructured":"Reijntjes B, van Suijlichem M, Woolderink JM,  Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: long-term outcomes of a randomised trial. Gynecol Oncol 2022;164:265\u2013270.10.1016\/j.ygyno.2021.12.019"},{"key":"B129","series-title":"J Minim Invasive Gynecol","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jmig.2013.01.005","article-title":"Laparoscopic treatment of endometrial cancer: systematic review","volume":"20","author":"He H","year":"2013","unstructured":"He H, Zeng D, Ou H,  Laparoscopic treatment of endometrial cancer: systematic review. J Minim Invasive Gynecol 2013;20:413\u2013423.10.1016\/j.jmig.2013.01.005"},{"key":"B130","series-title":"Asian Pac J Cancer Prev","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.7314\/APJCP.2013.14.4.2515","article-title":"Total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer: a meta-analysis","volume":"14","author":"Wang HL","year":"2013","unstructured":"Wang HL, Ren YF, Yang J,  Total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer: a meta-analysis. Asian Pac J Cancer Prev 2013;14:2515\u20132519.10.7314\/APJCP.2013.14.4.2515"},{"key":"B131","series-title":"ISRN Obstet Gynecol","doi-asserted-by":"publisher","first-page":"312982","DOI":"10.1155\/2013\/312982","article-title":"Minimally invasive surgery in gynecologic oncology","volume":"2013","author":"Mori KM","year":"2013","unstructured":"Mori KM, Neubauer NL. Minimally invasive surgery in gynecologic oncology. ISRN Obstet Gynecol 2013;2013:312982.10.1155\/2013\/312982"},{"key":"B132","series-title":"Cancer J","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/PPO.0b013e31828a3293","article-title":"Robotic surgery: gynecologic oncology","volume":"19","author":"Krill LS","year":"2013","unstructured":"Krill LS, Bristow RE. Robotic surgery: gynecologic oncology. Cancer J 2013;19:167\u2013176.10.1097\/PPO.0b013e31828a3293"},{"key":"B133","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ygyno.2011.09.038","article-title":"Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer","volume":"124","author":"ElSahwi KS","year":"2012","unstructured":"ElSahwi KS, Hooper C, De Leon MC,  Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecol Oncol 2012;124:260\u2013264.10.1016\/j.ygyno.2011.09.038"},{"key":"B134","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ygyno.2015.09.006","article-title":"Robotic versus laparoscopic versus open surgery in morbidly obese endometrial cancer patients - a comparative analysis of total charges and complication rates","volume":"139","author":"Chan JK","year":"2015","unstructured":"Chan JK, Gardner AB, Taylor K,  Robotic versus laparoscopic versus open surgery in morbidly obese endometrial cancer patients - a comparative analysis of total charges and complication rates. Gynecol Oncol 2015;139:300\u2013305.10.1016\/j.ygyno.2015.09.006"},{"key":"B135","series-title":"Eur J Obstet Gynecol Reprod Biol","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ejogrb.2012.07.006","article-title":"Comparison of perioperative outcomes and cost of robotic-assisted laparoscopy, laparoscopy and laparotomy for endometrial cancer","volume":"165","author":"Coronado PJ","year":"2012","unstructured":"Coronado PJ, Herraiz MA, Magrina JF,  Comparison of perioperative outcomes and cost of robotic-assisted laparoscopy, laparoscopy and laparotomy for endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2012;165:289\u2013294.10.1016\/j.ejogrb.2012.07.006"},{"key":"B136","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ygyno.2008.12.005","article-title":"Minimally invasive comprehensive surgical staging for endometrial cancer: robotics or laparoscopy?","volume":"113","author":"Seamon LG","year":"2009","unstructured":"Seamon LG, Cohn DE, Henretta MS,  Minimally invasive comprehensive surgical staging for endometrial cancer: robotics or laparoscopy? Gynecol Oncol 2009;113:36\u201341.10.1016\/j.ygyno.2008.12.005"},{"key":"B137","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ygyno.2008.08.022","article-title":"Comparison of outcomes and cost for endometrial cancer staging via traditional laparotomy, standard laparoscopy and robotic techniques","volume":"111","author":"Bell MC","year":"2008","unstructured":"Bell MC, Torgerson J, Seshadri-Kreaden U,  Comparison of outcomes and cost for endometrial cancer staging via traditional laparotomy, standard laparoscopy and robotic techniques. Gynecol Oncol 2008;111:407\u2013411.10.1016\/j.ygyno.2008.08.022"},{"key":"B138","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ygyno.2010.01.009","article-title":"Surgical outcomes of robotic-assisted surgical staging for endometrial cancer are equivalent to traditional laparoscopic staging at a minimally invasive surgical center","volume":"117","author":"Cardenas-Goicoechea J","year":"2010","unstructured":"Cardenas-Goicoechea J, Adams S, Bhat SB,  Surgical outcomes of robotic-assisted surgical staging for endometrial cancer are equivalent to traditional laparoscopic staging at a minimally invasive surgical center. Gynecol Oncol 2010;117:224\u2013228.10.1016\/j.ygyno.2010.01.009"},{"key":"B139","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1136\/ijgc-2020-001646","article-title":"Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer","volume":"30","author":"Abel MK","year":"2020","unstructured":"Abel MK, Chan JK, Chow S,  Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer. Int J Gynecol Cancer 2020;30:1347\u20131355.10.1136\/ijgc-2020-001646"},{"key":"B140","series-title":"Eur J Surg Oncol","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.ejso.2021.03.253","article-title":"Surgical complications occurring during minimally invasive sentinel lymph node detection in endometrial cancer patients. A systematic review of the literature and metanalysis","volume":"47","author":"Capozzi VA","year":"2021","unstructured":"Capozzi VA, Riemma G, Rosati A,  Surgical complications occurring during minimally invasive sentinel lymph node detection in endometrial cancer patients. A systematic review of the literature and metanalysis. Eur J Surg Oncol 2021;47:2142\u20132149.10.1016\/j.ejso.2021.03.253"},{"key":"B141","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ygyno.2012.11.005","article-title":"Analysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery","volume":"128","author":"Brudie LA","year":"2013","unstructured":"Brudie LA, Backes FJ, Ahmad S,  Analysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery. Gynecol Oncol 2013;128:309\u2013315.10.1016\/j.ygyno.2012.11.005"},{"key":"B142","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ygyno.2012.02.023","article-title":"Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging","volume":"125","author":"Backes FJ","year":"2012","unstructured":"Backes FJ, Brudie LA, Farrell MR,  Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. Gynecol Oncol 2012;125:546\u2013551.10.1016\/j.ygyno.2012.02.023"},{"key":"B143","series-title":"Curr Opin Oncol","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/CCO.0b013e328354e572","article-title":"Robotic surgery in gynecologic oncology","volume":"24","author":"Fleming ND","year":"2012","unstructured":"Fleming ND, Ramirez PT. Robotic surgery in gynecologic oncology. Curr Opin Oncol 2012;24:547\u2013553.10.1097\/CCO.0b013e328354e572"},{"key":"B144","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ygyno.2013.02.030","article-title":"Robotic surgical staging for endometrial and cervical cancers in medically ill patients","volume":"129","author":"Siesto G","year":"2013","unstructured":"Siesto G, Ornaghi S, Ied\u00e0 N,  Robotic surgical staging for endometrial and cervical cancers in medically ill patients. Gynecol Oncol 2013;129:593\u2013597.10.1016\/j.ygyno.2013.02.030"},{"key":"B145","series-title":"Obstet Gynecol Int","doi-asserted-by":"publisher","first-page":"973830","DOI":"10.1155\/2011\/973830","article-title":"Are costs of robot-assisted surgery warranted for gynecological procedures?","volume":"2011","author":"van Dam P","year":"2011","unstructured":"van Dam P, Hauspy J, Verkinderen L,  Are costs of robot-assisted surgery warranted for gynecological procedures? Obstet Gynecol Int 2011;2011:973830.10.1155\/2011\/973830"},{"key":"B146","series-title":"Obstet Gynecol Int","doi-asserted-by":"publisher","first-page":"852061","DOI":"10.1155\/2011\/852061","article-title":"Robotic surgery in gynecology: an updated systematic review","volume":"2011","author":"Weinberg L","year":"2011","unstructured":"Weinberg L, Rao S, Escobar PF. Robotic surgery in gynecology: an updated systematic review. Obstet Gynecol Int 2011;2011:852061.10.1155\/2011\/852061"},{"key":"B147","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ygyno.2011.11.006","article-title":"Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement","volume":"124","author":"Ramirez PT","year":"2012","unstructured":"Ramirez PT, Adams S, Boggess JF,  Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Gynecol Oncol 2012;124:180\u2013184.10.1016\/j.ygyno.2011.11.006"},{"key":"B148","series-title":"J Minim Invasive Gynecol","first-page":"157","article-title":"Guidelines for privileging for robotic-assisted gynecologic laparoscopy","volume":"21","year":"2014","unstructured":"AAGL Advancing Minimally Invasive Gynecology Worldwide. Guidelines for privileging for robotic-assisted gynecologic laparoscopy. J Minim Invasive Gynecol 2014;21:157\u2013167."},{"key":"B149","article-title":"Statement on Robotic Surgery by ACOG President James T. Breeden","unstructured":"American Congress of Obstetricians and Gynecologists. Statement on Robotic Surgery by ACOG President James T. Breeden. Accessed December 20, 2022. Available at: http:\/\/www.acog.org\/About-ACOG\/News-Room\/News-Releases\/2013\/Statement-on-Robotic-Surgery"},{"key":"B150","series-title":"Fertil Steril","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.fertnstert.2014.08.020","article-title":"Robotic-assisted surgery in gynecologic oncology","volume":"102","author":"Sinno AK","year":"2014","unstructured":"Sinno AK, Fader AN. Robotic-assisted surgery in gynecologic oncology. Fertil Steril 2014;102:922\u2013932.10.1016\/j.fertnstert.2014.08.020"},{"key":"B151","series-title":"J Minim Invasive Gynecol","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jmig.2013.11.010","article-title":"Systematic review of robotic surgery in gynecology: robotic techniques compared with laparoscopy and laparotomy","volume":"21","author":"Gala RB","year":"2014","unstructured":"Gala RB, Margulies R, Steinberg A,  Systematic review of robotic surgery in gynecology: robotic techniques compared with laparoscopy and laparotomy. J Minim Invasive Gynecol 2014;21:353\u2013361.10.1016\/j.jmig.2013.11.010"},{"key":"B152","article-title":"SGO position statement: morcellation","unstructured":"Society of Gynecologic Onconlogy. SGO position statement: morcellation. Accessed September 30, 2014. Available at: https:\/\/www.sgo.org\/newsroom\/position-statements-2\/morcellation\/"},{"key":"B153","article-title":"Power morcellation and occult malignancy in gynecologic surgery","unstructured":"ACOG. Power morcellation and occult malignancy in gynecologic surgery. Accessed January 23, 2023. Available at: https:\/\/www.sgo.org\/wp-content\/uploads\/2014\/04\/ACOG_Statement.pdf"},{"key":"B154","article-title":"FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine fibroids","unstructured":"U.S. Department of Health and Human Services. FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine fibroids. Accessed January 23, 2023. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm393689.htm"},{"key":"B155","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ygyno.2014.11.011","article-title":"Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis","volume":"137","author":"Bogani G","year":"2015","unstructured":"Bogani G, Cliby WA, Aletti GD. Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol 2015;137:167\u2013172.10.1016\/j.ygyno.2014.11.011"},{"key":"B156","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1200\/JCO.2008.19.8150","article-title":"Safety of ovarian preservation in premenopausal women with endometrial cancer","volume":"27","author":"Wright JD","year":"2009","unstructured":"Wright JD, Buck AM, Shah M,  Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 2009;27:1214\u20131219.10.1200\/JCO.2008.19.8150"},{"key":"B157","series-title":"Fertil Steril","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.fertnstert.2012.07.1142","article-title":"Safety of uterine and\/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery","volume":"98","author":"Koskas M","year":"2012","unstructured":"Koskas M, Bendifallah S, Luton D,  Safety of uterine and\/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertil Steril 2012;98:1229\u20131235.10.1016\/j.fertnstert.2012.07.1142"},{"key":"B158","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ygyno.2013.08.024","article-title":"Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study","volume":"131","author":"Lee TS","year":"2013","unstructured":"Lee TS, Lee JY, Kim JW,  Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study. Gynecol Oncol 2013;131:289\u2013293.10.1016\/j.ygyno.2013.08.024"},{"key":"B159","series-title":"Radiology","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1148\/radiol.2312021184","article-title":"Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning","volume":"231","author":"Manfredi R","year":"2004","unstructured":"Manfredi R, Mirk P, Maresca G,  Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology 2004;231:372\u2013378.10.1148\/radiol.2312021184"},{"key":"B160","series-title":"Radiol Clin North Am","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.rcl.2006.10.009","article-title":"Imaging of uterine cancer","volume":"45","author":"Akin O","year":"2007","unstructured":"Akin O, Mironov S, Pandit-Taskar N,  Imaging of uterine cancer. Radiol Clin North Am 2007;45:167\u2013182.10.1016\/j.rcl.2006.10.009"},{"key":"B161","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ygyno.2012.01.003","article-title":"Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review","volume":"125","author":"Gunderson CC","year":"2012","unstructured":"Gunderson CC, Fader AN, Carson KA,  Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012;125:477\u2013482.10.1016\/j.ygyno.2012.01.003"},{"key":"B162","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ygyno.2011.11.043","article-title":"Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature","volume":"125","author":"Baker J","year":"2012","unstructured":"Baker J, Obermair A, Gebski V,  Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 2012;125:263\u2013270.10.1016\/j.ygyno.2011.11.043"},{"key":"B163","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1200\/JCO.2012.47.5798","article-title":"Lives in the balance: women with cancer and the right to fertility care","volume":"31","author":"Gracia CR","year":"2013","unstructured":"Gracia CR, Jeruss JS. Lives in the balance: women with cancer and the right to fertility care. J Clin Oncol 2013;31:668\u2013669.10.1200\/JCO.2012.47.5798"},{"key":"B164","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/JCO.2006.08.8344","article-title":"Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women","volume":"25","author":"Ushijima K","year":"2007","unstructured":"Ushijima K, Yahata H, Yoshikawa H,  Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798\u20132803.10.1200\/JCO.2006.08.8344"},{"key":"B165","series-title":"Obstet Gynecol","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1097\/AOG.0b013e31828d6186","article-title":"Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma","volume":"121","author":"Hubbs JL","year":"2013","unstructured":"Hubbs JL, Saig RM, Abaid LN,  Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma. Obstet Gynecol 2013;121:1172\u20131180.10.1097\/AOG.0b013e31828d6186"},{"key":"B166","series-title":"Obstet Gynecol","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1097\/AOG.0b013e31826bb121","article-title":"Management of endometrial precancers","volume":"120","author":"Trimble CL","year":"2012","unstructured":"Trimble CL, Method M, Leitao M,  Management of endometrial precancers. Obstet Gynecol 2012;120:1160\u20131175.10.1097\/AOG.0b013e31826bb121"},{"key":"B167","series-title":"Obstet Gynecol Int","doi-asserted-by":"publisher","first-page":"676032","DOI":"10.1155\/2012\/676032","article-title":"Controversies in the management of endometrial carcinoma: an update","volume":"2012","author":"Mehasseb MK","year":"2012","unstructured":"Mehasseb MK, Latimer JA. Controversies in the management of endometrial carcinoma: an update. Obstet Gynecol Int 2012;2012:676032.10.1155\/2012\/676032"},{"key":"B168","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/IGC.0b013e3181aae1fb","article-title":"Conservative treatment with progestin and pregnancy outcomes in endometrial cancer","volume":"19","author":"Hahn HS","year":"2009","unstructured":"Hahn HS, Yoon SG, Hong JS,  Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 2009;19:1068\u20131073.10.1111\/IGC.0b013e3181aae1fb"},{"key":"B169","series-title":"Eur J Cancer","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ejca.2012.09.017","article-title":"Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)","volume":"49","author":"Park JY","year":"2013","unstructured":"Park JY, Kim DY, Kim JH,  Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer 2013;49:868\u2013874.10.1016\/j.ejca.2012.09.017"},{"key":"B170","series-title":"J Cancer","doi-asserted-by":"publisher","first-page":"754","DOI":"10.7150\/jca.52797","article-title":"Diagnostic accuracy of MRI for detecting cervical invasion in patients with endometrial carcinoma: a meta- analysis","volume":"12","author":"Bi Q","year":"2021","unstructured":"Bi Q, Bi G, Wang J,  Diagnostic accuracy of MRI for detecting cervical invasion in patients with endometrial carcinoma: a meta- analysis. J Cancer 2021;12:754\u2013764.10.7150\/jca.52797"},{"key":"B171","series-title":"Acad Radiol","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.acra.2019.09.018","article-title":"The diagnostic value of MRI for preoperative staging in patients with endometrial cancer: a meta-analysis","volume":"27","author":"Bi Q","year":"2020","unstructured":"Bi Q, Chen Y, Wu K,  The diagnostic value of MRI for preoperative staging in patients with endometrial cancer: a meta-analysis. Acad Radiol 2020;27:960\u2013968.10.1016\/j.acra.2019.09.018"},{"key":"B172","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1006\/gyno.1993.1297","article-title":"Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement","volume":"51","author":"Boente MP","year":"1993","unstructured":"Boente MP, Yordan EL Jr, McIntosh DG,  Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol 1993;51:316\u2013322.10.1006\/gyno.1993.1297"},{"key":"B173","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1046\/j.1525-1438.2001.01061.x","article-title":"Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy","volume":"11","author":"Sartori E","year":"2001","unstructured":"Sartori E, Gadducci A, Landoni F,  Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer 2001;11:430\u2013437.10.1046\/j.1525-1438.2001.01061.x"},{"key":"B174","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ygyno.2010.04.005","article-title":"Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis","volume":"118","author":"Barlin JN","year":"2010","unstructured":"Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 2010;118:14\u201318.10.1016\/j.ygyno.2010.04.005"},{"key":"B175","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ygyno.2004.03.015","article-title":"Optimal surgical cytoreduction in patients with stage III and stage IV endometrial carcinoma: a study of morbidity and survival","volume":"93","author":"Lambrou NC","year":"2004","unstructured":"Lambrou NC, G\u00f3mez-Mar\u00edn O, Mirhashemi R,  Optimal surgical cytoreduction in patients with stage III and stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol 2004;93:653\u2013658.10.1016\/j.ygyno.2004.03.015"},{"key":"B176","series-title":"Am J Obstet Gynecol","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2021.04.254","article-title":"Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis","volume":"225","author":"Albright BB","year":"2021","unstructured":"Albright BB, Monuszko KA, Kaplan SJ,  Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol 2021;225:237.e1\u2013237.e24.10.1016\/j.ajog.2021.04.254"},{"key":"B177","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma DA","year":"2019","unstructured":"Palma DA, Olson R, Harrow S,  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019;393:2051\u20132058.10.1016\/S0140-6736(18)32487-5"},{"key":"B178","series-title":"Crit Rev Oncol Hematol","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.critrevonc.2005.11.002","article-title":"Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies","volume":"58","author":"Gadducci A","year":"2006","unstructured":"Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 2006;58:242\u2013256.10.1016\/j.critrevonc.2005.11.002"},{"key":"B179","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1006\/gyno.1996.0123","article-title":"Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium","volume":"61","author":"Fishman DA","year":"1996","unstructured":"Fishman DA, Roberts KB, Chambers JT,  Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol 1996;61:189\u2013196.10.1006\/gyno.1996.0123"},{"key":"B180","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ijrobp.2007.10.026","article-title":"High-dose-rate Rotte \u201cY\u201d applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results","volume":"71","author":"Coon D","year":"2008","unstructured":"Coon D, Beriwal S, Heron DE,  High-dose-rate Rotte \u201cY\u201d applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results. Int J Radiat Oncol Biol Phys 2008;71:779\u2013783.10.1016\/j.ijrobp.2007.10.026"},{"key":"B181","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ijrobp.2005.04.036","article-title":"Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma","volume":"63","author":"Niazi TM","year":"2005","unstructured":"Niazi TM, Souhami L, Portelance L,  Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. Int J Radiat Oncol Biol Phys 2005;63:1108\u20131113.10.1016\/j.ijrobp.2005.04.036"},{"key":"B182","series-title":"Eur J Cancer","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejca.2016.07.005","article-title":"Systemic review: radiation therapy alone in medical non-operable endometrial carcinoma","volume":"65","author":"van der Steen-Banasik E","year":"2016","unstructured":"van der Steen-Banasik E, Christiaens M, Shash E,  Systemic review: radiation therapy alone in medical non-operable endometrial carcinoma. Eur J Cancer 2016;65:172\u2013181.10.1016\/j.ejca.2016.07.005"},{"key":"B183","series-title":"Best Pract Res Clin Obstet Gynaecol","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/beog.2001.0167","article-title":"Palliative radiation therapy for gynaecological malignancies","volume":"15","author":"Smith SC","year":"2001","unstructured":"Smith SC, Koh WJ. Palliative radiation therapy for gynaecological malignancies. Best Pract Res Clin Obstet Gynaecol 2001;15:265\u2013278.10.1053\/beog.2001.0167"},{"key":"B184","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"24","author":"Randall ME","year":"2006","unstructured":"Randall ME, Filiaci VL, Muss H,  Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2006;24:36\u201344.10.1200\/JCO.2004.00.7617"},{"key":"B185","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ygyno.2008.11.014","article-title":"A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study","volume":"112","author":"Homesley HD","year":"2009","unstructured":"Homesley HD, Filiaci V, Gibbons SK,  A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 2009;112:543\u2013552.10.1016\/j.ygyno.2008.11.014"},{"key":"B186","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ygyno.2009.06.005","article-title":"A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer","volume":"114","author":"Secord AA","year":"2009","unstructured":"Secord AA, Havrilesky LJ, O\u2019Malley DM,  A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol 2009;114:442\u2013447.10.1016\/j.ygyno.2009.06.005"},{"key":"B187","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ijrobp.2014.11.022","article-title":"Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials","volume":"91","author":"Creutzberg CL","year":"2015","unstructured":"Creutzberg CL, van Stiphout RG, Nout RA,  Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys 2015;91:530\u2013539.10.1016\/j.ijrobp.2014.11.022"},{"key":"B188","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ygyno.2014.06.003","article-title":"Endometrial cancer: a review and current management strategies: part II","volume":"134","author":"Burke WM","year":"2014","unstructured":"Burke WM, Orr J, Leitao M,  Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol 2014;134:393\u2013402.10.1016\/j.ygyno.2014.06.003"},{"key":"B189","series-title":"Curr Oncol Rep","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s11912-011-0191-y","article-title":"The role of radiotherapy in endometrial cancer: current evidence and trends","volume":"13","author":"Creutzberg CL","year":"2011","unstructured":"Creutzberg CL, Nout RA. The role of radiotherapy in endometrial cancer: current evidence and trends. Curr Oncol Rep 2011;13:472\u2013478.10.1007\/s11912-011-0191-y"},{"key":"B190","series-title":"Pract Radiat Oncol","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.prro.2014.01.003","article-title":"The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline","volume":"4","author":"Klopp A","year":"2014","unstructured":"Klopp A, Smith BD, Alektiar K,  The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2014;4:137\u2013144.10.1016\/j.prro.2014.01.003"},{"key":"B191","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1200\/JCO.2015.62.5459","article-title":"Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based guideline","volume":"33","author":"Meyer LA","year":"2015","unstructured":"Meyer LA, Bohlke K, Powell MA,  Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based guideline. J Clin Oncol 2015;33:2908\u20132913.10.1200\/JCO.2015.62.5459"},{"key":"B192","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ygyno.2008.11.012","article-title":"The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma","volume":"112","author":"Neubauer NL","year":"2009","unstructured":"Neubauer NL, Havrilesky LJ, Calingaert B,  The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. Gynecol Oncol 2009;112:511\u2013516.10.1016\/j.ygyno.2008.11.012"},{"key":"B193","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1006\/gyno.1996.0165","article-title":"The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma","volume":"61","author":"Gretz HF III","year":"1996","unstructured":"Gretz HF III, Economos K, Husain A,  The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol 1996;61:409\u2013415.10.1006\/gyno.1996.0165"},{"key":"B194","series-title":"Obstet Gynecol","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/01.AOG.0000149151.74863.c4","article-title":"Surgical staging for patients presenting with grade 1 endometrial carcinoma","volume":"105","author":"Ben-Shachar I","year":"2005","unstructured":"Ben-Shachar I, Pavelka J, Cohn DE,  Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol 2005;105:487\u2013493.10.1097\/01.AOG.0000149151.74863.c4"},{"key":"B195","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout RA","year":"2010","unstructured":"Nout RA, Smit VT, Putter H,  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816\u2013823.10.1016\/S0140-6736(09)62163-2"},{"key":"B196","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ygyno.2014.12.012","article-title":"Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study","volume":"136","author":"Elshaikh MA","year":"2015","unstructured":"Elshaikh MA, Al-Wahab Z, Mahdi H,  Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study. Gynecol Oncol 2015;136:235\u2013239.10.1016\/j.ygyno.2014.12.012"},{"key":"B197","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial","volume":"355","author":"Creutzberg CL","year":"2000","unstructured":"Creutzberg CL, van Putten WL, Koper PC,  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet 2000;355:1404\u20131411.10.1016\/S0140-6736(00)02139-5"},{"key":"B198","series-title":"Obstet Gynecol","first-page":"419","article-title":"Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients","volume":"56","author":"Aalders J","year":"1980","unstructured":"Aalders J, Abeler V, Kolstad P,  Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419\u2013427."},{"key":"B199","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Keys HM","year":"2004","unstructured":"Keys HM, Roberts JA, Brunetto VL,  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744\u2013751.10.1016\/j.ygyno.2003.11.048"},{"key":"B200","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1200\/JCO.2004.08.159","article-title":"Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial","volume":"22","author":"Creutzberg CL","year":"2004","unstructured":"Creutzberg CL, van Putten WL, W\u00e1rl\u00e1m-Rodenhuis CC,  Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 2004;22:1234\u20131241.10.1200\/JCO.2004.08.159"},{"key":"B201","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ijrobp.2005.03.007","article-title":"Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review","volume":"63","author":"Scholten AN","year":"2005","unstructured":"Scholten AN, van Putten WL, Beerman H,  Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834\u2013838.10.1016\/j.ijrobp.2005.03.007"},{"key":"B202","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0140-6736(08)61767-5","article-title":"Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis","volume":"373","author":"Blake P","year":"2009","unstructured":"Blake P, Swart AM, Orton J,  Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373:137\u2013146.10.1016\/S0140-6736(08)61767-5"},{"key":"B203","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0140-6736(08)61768-7","article-title":"Treatment of early endometrial carcinoma: is less more?","volume":"373","author":"H\u00f6ckel M","year":"2009","unstructured":"H\u00f6ckel M, Dornh\u00f6fer N. Treatment of early endometrial carcinoma: is less more? Lancet 2009;373:97\u201399.10.1016\/S0140-6736(08)61768-7"},{"key":"B204","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1016\/j.ijrobp.2011.04.013","article-title":"Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma","volume":"81","author":"Creutzberg CL","year":"2011","unstructured":"Creutzberg CL, Nout RA, Lybeert ML,  Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e631\u2013638.10.1016\/j.ijrobp.2011.04.013"},{"key":"B205","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijrobp.2004.09.054","article-title":"Intravaginal brachytherapy alone for intermediate-risk endometrial cancer","volume":"62","author":"Alektiar KM","year":"2005","unstructured":"Alektiar KM, Venkatraman E, Chi DS,  Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2005;62:111\u2013117.10.1016\/j.ijrobp.2004.09.054"},{"key":"B206","series-title":"Brachytherapy","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.brachy.2011.08.005","article-title":"American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy","volume":"11","author":"Small W Jr","year":"2012","unstructured":"Small W Jr, Beriwal S, Demanes DJ,  American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy 2012;11:58\u201367.10.1016\/j.brachy.2011.08.005"},{"key":"B207","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1200\/JCO.2013.48.8023","article-title":"Long-term outcomes after pelvic radiation for early-stage endometrial cancer","volume":"31","author":"Onsrud M","year":"2013","unstructured":"Onsrud M, Cvancarova M, Hellebust TP,  Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J Clin Oncol 2013;31:3951\u20133956.10.1200\/JCO.2013.48.8023"},{"key":"B208","series-title":"Eur J Cancer","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.ejca.2011.11.014","article-title":"Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data","volume":"48","author":"Nout RA","year":"2012","unstructured":"Nout RA, Putter H, J\u00fcrgenliemk-Schulz IM,  Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer 2012;48:1638\u20131648.10.1016\/j.ejca.2011.11.014"},{"key":"B209","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ygyno.2007.08.055","article-title":"Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients","volume":"107","author":"R\u00f6per B","year":"2007","unstructured":"R\u00f6per B, Astner ST, Heydemann-Obradovic A,  Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. Gynecol Oncol 2007;107:541\u2013548.10.1016\/j.ygyno.2007.08.055"},{"key":"B210","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.2008.20.2424","article-title":"Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial","volume":"27","author":"Nout RA","year":"2009","unstructured":"Nout RA, Putter H, J\u00fcrgenliemk-Schulz IM,  Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009;27:3547\u20133556.10.1200\/JCO.2008.20.2424"},{"key":"B211","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ygyno.2009.06.027","article-title":"Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation","volume":"116","author":"McCloskey SA","year":"2010","unstructured":"McCloskey SA, Tchabo NE, Malhotra HK,  Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol 2010;116:404\u2013407.10.1016\/j.ygyno.2009.06.027"},{"key":"B212","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ygyno.2014.03.554","article-title":"Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer","volume":"133","author":"Dunn EF","year":"2014","unstructured":"Dunn EF, Geye H, Platta CS,  Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer. Gynecol Oncol 2014;133:494\u2013498.10.1016\/j.ygyno.2014.03.554"},{"key":"B213","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/ijgc-2020-001199","article-title":"External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis","volume":"30","author":"Narasimhulu DM","year":"2020","unstructured":"Narasimhulu DM, Cope A, Riaz IB,  External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2020;30:797\u2013805.10.1136\/ijgc-2020-001199"},{"key":"B214","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall ME","year":"2019","unstructured":"Randall ME, Filiaci V, McMeekin DS,  Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol 2019;37:1810\u20131818.10.1200\/JCO.18.01575"},{"key":"B215","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.ijrobp.2011.03.054","article-title":"The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer","volume":"82","author":"Chino JP","year":"2012","unstructured":"Chino JP, Jones E, Berchuck A,  The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. Int J Radiat Oncol Biol Phys 2012;82:1872\u20131879.10.1016\/j.ijrobp.2011.03.054"},{"key":"B216","series-title":"JAMA","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1001\/jama.295.4.389","article-title":"Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma","volume":"295","author":"Lee CM","year":"2006","unstructured":"Lee CM, Szabo A, Shrieve DC,  Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 2006;295:389\u2013397.10.1001\/jama.295.4.389"},{"key":"B217","series-title":"BJOG","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/j.1471-0528.2007.01332.x","article-title":"Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis","volume":"114","author":"Johnson N","year":"2007","unstructured":"Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007;114:1313\u20131320.10.1111\/j.1471-0528.2007.01332.x"},{"key":"B218","series-title":"Cochrane Database Syst Rev","first-page":"CD003916","article-title":"Adjuvant radiotherapy for stage I endometrial cancer","volume":"2","author":"Kong A","year":"2007","unstructured":"Kong A, Johnson N, Cornes P,  Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2007;2:CD003916."},{"key":"B219","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/jnci\/djs374","article-title":"Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis","volume":"104","author":"Kong A","year":"2012","unstructured":"Kong A, Johnson N, Kitchener HC,  Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst 2012;104:1625\u20131634.10.1093\/jnci\/djs374"},{"key":"B220","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/jnci\/djs434","article-title":"The role of adjuvant radiation therapy for stage I endometrial cancer: does meta-analysis reveal the answer?","volume":"104","author":"Eifel PJ","year":"2012","unstructured":"Eifel PJ. The role of adjuvant radiation therapy for stage I endometrial cancer: does meta-analysis reveal the answer? J Natl Cancer Inst 2012;104:1615\u20131616.10.1093\/jnci\/djs434"},{"key":"B221","series-title":"Eur J Obstet Gynecol Reprod Biol","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejogrb.2013.06.009","article-title":"The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis","volume":"170","author":"Park HJ","year":"2013","unstructured":"Park HJ, Nam EJ, Kim S,  The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2013;170:39\u201344.10.1016\/j.ejogrb.2013.06.009"},{"key":"B222","series-title":"Eur J Cancer","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","article-title":"Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies","volume":"46","author":"Hogberg T","year":"2010","unstructured":"Hogberg T, Signorelli M, de Oliveira CF,  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer 2010;46:2422\u20132431.10.1016\/j.ejca.2010.06.002"},{"key":"B223","series-title":"Cochrane Database Syst Rev","first-page":"CD003175","article-title":"Adjuvant chemotherapy for endometrial cancer after hysterectomy","volume":"2011","author":"Johnson N","year":"2011","unstructured":"Johnson N, Bryant A, Miles T,  Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011;2011:CD003175."},{"key":"B224","series-title":"Clin Oncol (R Coll Radiol)","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.clon.2008.04.001","article-title":"Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials","volume":"20","author":"Hogberg T","year":"2008","unstructured":"Hogberg T. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials. Clin Oncol (R Coll Radiol) 2008;20:463\u2013469.10.1016\/j.clon.2008.04.001"},{"key":"B225","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ygyno.2012.10.010","article-title":"A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer","volume":"128","author":"Secord AA","year":"2013","unstructured":"Secord AA, Geller MA, Broadwater G,  A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol 2013;128:65\u201370.10.1016\/j.ygyno.2012.10.010"},{"key":"B226","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1002\/1097-0142(19930601)71:11<3697::AID-CNCR2820711137>3.0.CO;2-U","article-title":"Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence","volume":"71","author":"Greven KM","year":"1993","unstructured":"Greven KM, Lanciano RM, Corn B,  Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer 1993;71:3697\u20133702.10.1002\/1097-0142(19930601)71:11<3697::AID-CNCR2820711137>3.0.CO;2-U"},{"key":"B227","series-title":"Cancer Chemother Pharmacol","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00280-013-2276-9","article-title":"Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology)","volume":"72","author":"Mustea A","year":"2013","unstructured":"Mustea A, Koensgen D, Belau A,  Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology). Cancer Chemother Pharmacol 2013;72:975\u2013983.10.1007\/s00280-013-2276-9"},{"key":"B228","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ygyno.2013.09.012","article-title":"The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma","volume":"131","author":"Jutzi L","year":"2013","unstructured":"Jutzi L, Hoskins P, Lim P,  The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma. Gynecol Oncol 2013;131:581\u2013585.10.1016\/j.ygyno.2013.09.012"},{"key":"B229","series-title":"Lancet Oncol","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S1470-2045(16)30120-6","article-title":"Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial","volume":"17","author":"de Boer SM","year":"2016","unstructured":"de Boer SM, Powell ME, Mileshkin L,  Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2016;17:1114\u20131126.10.1016\/S1470-2045(16)30120-6"},{"key":"B230","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/0360-3016(91)90744-O","article-title":"Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma","volume":"21","author":"Gibbons S","year":"1991","unstructured":"Gibbons S, Martinez A, Schray M,  Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J Radiat Oncol Biol Phys 1991;21:1019\u20131025.10.1016\/0360-3016(91)90744-O"},{"key":"B231","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0090-8258(83)90164-6","article-title":"Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation","volume":"16","author":"Greer BE","year":"1983","unstructured":"Greer BE, Hamberger AD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation. Gynecol Oncol 1983;16:365\u2013373.10.1016\/0090-8258(83)90164-6"},{"key":"B232","series-title":"J Gynecol Oncol","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3802\/jgo.2012.23.1.22","article-title":"Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer","volume":"23","author":"Abaid LN","year":"2012","unstructured":"Abaid LN, Rettenmaier MA, Brown JV III,  Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer. J Gynecol Oncol 2012;23:22\u201327.10.3802\/jgo.2012.23.1.22"},{"key":"B233","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ygyno.2010.12.338","article-title":"A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a \u201cSandwich\u201d method for stage III, IV, and recurrent endometrial cancer","volume":"121","author":"Geller MA","year":"2011","unstructured":"Geller MA, Ivy JJ, Ghebre R,  A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a \u201cSandwich\u201d method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol 2011;121:112\u2013117.10.1016\/j.ygyno.2010.12.338"},{"key":"B234","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/IGC.0b013e3182915c3e","article-title":"Survival analysis of endometrial cancer patients with positive lymph nodes","volume":"23","author":"Brown AP","year":"2013","unstructured":"Brown AP, Gaffney DK, Dodson MK,  Survival analysis of endometrial cancer patients with positive lymph nodes. Int J Gynecol Cancer 2013;23:861\u2013868.10.1097\/IGC.0b013e3182915c3e"},{"key":"B235","series-title":"Am J Clin Oncol","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/COC.0b013e31829c12be","article-title":"Survival analysis of cancer patients with FIGO stage IIIA endometrial cancer","volume":"38","author":"Lum MM","year":"2015","unstructured":"Lum MM, Belnap TW, Frandsen J,  Survival analysis of cancer patients with FIGO stage IIIA endometrial cancer. Am J Clin Oncol 2015;38:283\u2013288.10.1097\/COC.0b013e31829c12be"},{"key":"B236","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ygyno.2015.11.021","article-title":"Adjuvant concurrent chemoradiation followed by chemotherapy for high-risk endometrial cancer","volume":"140","author":"Ren Y","year":"2016","unstructured":"Ren Y, Huang X, Shan B,  Adjuvant concurrent chemoradiation followed by chemotherapy for high-risk endometrial cancer. Gynecol Oncol 2016;140:58\u201363.10.1016\/j.ygyno.2015.11.021"},{"key":"B237","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ygyno.2006.02.007","article-title":"Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin\/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer","volume":"103","author":"Greven K","year":"2006","unstructured":"Greven K, Winter K, Underhill K,  Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin\/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006;103:155\u2013159.10.1016\/j.ygyno.2006.02.007"},{"key":"B238","series-title":"Lancet Oncol","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer SM","year":"2019","unstructured":"de Boer SM, Powell ME, Mileshkin L,  Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019;20:1273\u20131285.10.1016\/S1470-2045(19)30395-X"},{"key":"B239","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.ijrobp.2020.10.030","article-title":"Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial","volume":"109","author":"Post CCB","year":"2021","unstructured":"Post CCB, de Boer SM, Powell ME,  Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial. Int J Radiat Oncol Biol Phys 2021;109:975\u2013986.10.1016\/j.ijrobp.2020.10.030"},{"key":"B240","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei D","year":"2019","unstructured":"Matei D, Filiaci V, Randall ME,  Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 2019;380:2317\u20132326.10.1056\/NEJMoa1813181"},{"key":"B241","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo A","year":"2020","unstructured":"Le\u00f3n-Castillo A, de Boer SM, Powell ME,  Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020;38:3388\u20133397.10.1200\/JCO.20.00549"},{"key":"B242","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ygyno.2018.07.020","article-title":"Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial","volume":"151","author":"Wortman BG","year":"2018","unstructured":"Wortman BG, Bosse T, Nout RA,  Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Oncol 2018;151:69\u201375.10.1016\/j.ygyno.2018.07.020"},{"key":"B243","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1006\/gyno.1999.5536","article-title":"Pelvic exenteration for recurrent endometrial cancer","volume":"75","author":"Barakat RR","year":"1999","unstructured":"Barakat RR, Goldman NA, Patel DA,  Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 1999;75:99\u2013102.10.1006\/gyno.1999.5536"},{"key":"B244","series-title":"J Surg Oncol","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jso.20686","article-title":"Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers","volume":"95","author":"Fleisch MC","year":"2007","unstructured":"Fleisch MC, Pantke P, Beckmann MW,  Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol 2007;95:476\u2013484.10.1002\/jso.20686"},{"key":"B245","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ygyno.2005.10.018","article-title":"Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes","volume":"101","author":"Dowdy SC","year":"2006","unstructured":"Dowdy SC, Mariani A, Cliby WA,  Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol 2006;101:280\u2013286.10.1016\/j.ygyno.2005.10.018"},{"key":"B246","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ijrobp.2007.03.021","article-title":"Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies","volume":"69","author":"Tran PT","year":"2007","unstructured":"Tran PT, Su Z, Hara W,  Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys 2007;69:504\u2013511.10.1016\/j.ijrobp.2007.03.021"},{"key":"B247","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0090-8258(03)00126-4","article-title":"Survival after relapse in patients with endometrial cancer: results from a randomized trial","volume":"89","author":"Creutzberg CL","year":"2003","unstructured":"Creutzberg CL, van Putten WL, Koper PC,  Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003;89:201\u2013209.10.1016\/S0090-8258(03)00126-4"},{"key":"B248","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ijrobp.2005.02.004","article-title":"Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer","volume":"63","author":"Lin LL","year":"2005","unstructured":"Lin LL, Grigsby PW, Powell MA,  Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. Int J Radiat Oncol Biol Phys 2005;63:500\u2013504.10.1016\/j.ijrobp.2005.02.004"},{"key":"B249","series-title":"J Obstet Gynaecol Can","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S1701-2163(16)35320-8","article-title":"Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study","volume":"34","author":"Altman AD","year":"2012","unstructured":"Altman AD, Thompson J, Nelson G,  Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study. J Obstet Gynaecol Can 2012;34:664\u2013672.10.1016\/S1701-2163(16)35320-8"},{"key":"B250","series-title":"Curr Med Res Opin","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1185\/03007990902860549","article-title":"Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma","volume":"25","author":"Barker LC","year":"2009","unstructured":"Barker LC, Brand IR, Crawford SM. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin 2009;25:1105\u20131109.10.1185\/03007990902860549"},{"key":"B251","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Fiorica JV","year":"2004","unstructured":"Fiorica JV, Brunetto VL, Hanjani P,  Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:10\u201314.10.1016\/j.ygyno.2003.11.008"},{"key":"B252","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Whitney CW","year":"2004","unstructured":"Whitney CW, Brunetto VL, Zaino RJ,  Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:4\u20139.10.1016\/j.ygyno.2003.09.018"},{"key":"B253","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2003.11.014","article-title":"What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer?","volume":"92","author":"Herzog TJ","year":"2004","unstructured":"Herzog TJ. What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer? Gynecol Oncol 2004;92:1\u20133.10.1016\/j.ygyno.2003.11.014"},{"key":"B254","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study","volume":"106","author":"Singh M","year":"2007","unstructured":"Singh M, Zaino RJ, Filiaci VJ,  Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2007;106:325\u2013333.10.1016\/j.ygyno.2007.03.042"},{"key":"B255","series-title":"Acta Oncol","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3109\/02841868909092271","article-title":"Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature","volume":"28","author":"Kauppila A","year":"1989","unstructured":"Kauppila A. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol 1989;28:561\u2013566.10.3109\/02841868909092271"},{"key":"B256","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1200\/JCO.1999.17.6.1736","article-title":"Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group","volume":"17","author":"Thigpen JT","year":"1999","unstructured":"Thigpen JT, Brady MF, Alvarez RD,  Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17:1736\u20131744.10.1200\/JCO.1999.17.6.1736"},{"key":"B257","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1525-1438.2007.00897.x","article-title":"Hormone therapy in advanced and recurrent endometrial cancer: a systematic review","volume":"17","author":"Decruze SB","year":"2007","unstructured":"Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007;17:964\u2013978.10.1111\/j.1525-1438.2007.00897.x"},{"key":"B258","series-title":"Expert Rev Anticancer Ther","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1586\/era.09.54","article-title":"Systemic therapy for recurrent endometrial cancer: a review of North American trials","volume":"9","author":"Dellinger TH","year":"2009","unstructured":"Dellinger TH, Monk BJ. Systemic therapy for recurrent endometrial cancer: a review of North American trials. Expert Rev Anticancer Ther 2009;9:905\u2013916.10.1586\/era.09.54"},{"key":"B259","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1200\/JCO.2001.19.2.364","article-title":"Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"19","author":"Thigpen T","year":"2001","unstructured":"Thigpen T, Brady MF, Homesley HD,  Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001;19:364\u2013367.10.1200\/JCO.2001.19.2.364"},{"key":"B260","series-title":"Am J Clin Oncol","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00000421-200102000-00007","article-title":"Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group study (E4882)","volume":"24","author":"Pandya KJ","year":"2001","unstructured":"Pandya KJ, Yeap BY, Weiner LM,  Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group study (E4882). Am J Clin Oncol 2001;24:43\u201346.10.1097\/00000421-200102000-00007"},{"key":"B261","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz BM","year":"2015","unstructured":"Slomovitz BM, Jiang Y, Yates MS,  Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2015;33:930\u2013936.10.1200\/JCO.2014.58.3401"},{"key":"B262","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG Foundation study","volume":"164","author":"Slomovitz BM","year":"2022","unstructured":"Slomovitz BM, Filiaci VL, Walker JL,  A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG Foundation study. Gynecol Oncol 2022;164:481\u2013491.10.1016\/j.ygyno.2021.12.031"},{"key":"B263","series-title":"Hematol Oncol Clin North Am","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0889-8588(05)70159-3","article-title":"Hormonal treatment of endometrial cancer","volume":"13","author":"Quinn MA","year":"1999","unstructured":"Quinn MA. Hormonal treatment of endometrial cancer. Hematol Oncol Clin North Am 1999;13:163\u2013187; ix.10.1016\/S0889-8588(05)70159-3"},{"key":"B264","series-title":"Semin Oncol","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/j.seminoncol.2008.12.006","article-title":"Management of advanced-stage and recurrent endometrial cancer","volume":"36","author":"Ray M","year":"2009","unstructured":"Ray M, Fleming G. Management of advanced-stage and recurrent endometrial cancer. Semin Oncol 2009;36:145\u2013154.10.1053\/j.seminoncol.2008.12.006"},{"key":"B265","series-title":"Ann Oncol","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdl417","article-title":"Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration","volume":"18","author":"Humber CE","year":"2007","unstructured":"Humber CE, Tierney JF, Symonds RP,  Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007;18:409\u2013420.10.1093\/annonc\/mdl417"},{"key":"B266","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ygyno.2010.08.022","article-title":"Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184","volume":"119","author":"Cella D","year":"2010","unstructured":"Cella D, Huang H, Homesley HD,  Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol 2010;119:538\u2013542.10.1016\/j.ygyno.2010.08.022"},{"key":"B267","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.2004.07.184","article-title":"Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"22","author":"Fleming GF","year":"2004","unstructured":"Fleming GF, Brunetto VL, Cella D,  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004;22:2159\u20132166.10.1200\/JCO.2004.07.184"},{"key":"B268","series-title":"Gynecol Oncol","first-page":"13","article-title":"The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): a randomized phase III NRG\/ Gynecologic Oncology Group (GOG) study","volume":"154","author":"Spirtos NM","year":"2019","unstructured":"Spirtos NM, Enserro D, Homesley HD,  The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): a randomized phase III NRG\/ Gynecologic Oncology Group (GOG) study. Gynecol Oncol 2019;154:13\u201321."},{"key":"B269","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1525-1438.2006.00746.x","article-title":"Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study","volume":"17","author":"Sovak MA","year":"2007","unstructured":"Sovak MA, Dupont J, Hensley ML,  Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer 2007;17:197\u2013203.10.1111\/j.1525-1438.2006.00746.x"},{"key":"B270","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ygyno.2008.01.028","article-title":"Carboplatin and paclitaxel in advanced or metastatic endometrial cancer","volume":"109","author":"Pectasides D","year":"2008","unstructured":"Pectasides D, Xiros N, Papaxoinis G,  Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 2008;109:250\u2013254.10.1016\/j.ygyno.2008.01.028"},{"key":"B271","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/j.1525-1438.2007.01094.x","article-title":"Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up","volume":"18","author":"Sorbe B","year":"2008","unstructured":"Sorbe B, Andersson H, Boman K,  Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 2008;18:803\u2013808.10.1111\/j.1525-1438.2007.01094.x"},{"key":"B272","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller DS","year":"2020","unstructured":"Miller DS, Filiaci VL, Mannel RS,  Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209). J Clin Oncol 2020;38:3841\u20133850.10.1200\/JCO.20.01076"},{"key":"B273","series-title":"Ann Oncol","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/annonc\/mdq401","article-title":"Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)","volume":"22","author":"Nomura H","year":"2011","unstructured":"Nomura H, Aoki D, Takahashi F,  Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). Ann Oncol 2011;22:636\u2013642.10.1093\/annonc\/mdq401"},{"key":"B274","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ygyno.2014.12.004","article-title":"A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)","volume":"136","author":"Simpkins F","year":"2015","unstructured":"Simpkins F, Drake R, Escobar PF,  A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecol Oncol 2015;136:240\u2013245.10.1016\/j.ygyno.2014.12.004"},{"key":"B275","series-title":"Int J Gynecol Cancer","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/IGC.0000000000000891","article-title":"Paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma","volume":"27","author":"Rose PG","year":"2017","unstructured":"Rose PG, Ali S, Moslemi-Kebria M,  Paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma. Int J Gynecol Cancer 2017;27:452\u2013458.10.1097\/IGC.0000000000000891"},{"key":"B276","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ygyno.2019.10.013","article-title":"Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - a randomized phase II trial","volume":"155","author":"Lorusso D","year":"2019","unstructured":"Lorusso D, Ferrandina G, Colombo N,  Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - a randomized phase II trial. Gynecol Oncol 2019;155:406\u2013412.10.1016\/j.ygyno.2019.10.013"},{"key":"B277","series-title":"Balkan Med J","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5152\/balkanmedj.2021.20121","article-title":"Efficacy and safety of bevacizumab-combined chemotherapy for advanced and recurrent endometrial cancer: a systematic review and meta-analysis","volume":"38","author":"Chen H","year":"2021","unstructured":"Chen H, Liang M, Min J. Efficacy and safety of bevacizumab-combined chemotherapy for advanced and recurrent endometrial cancer: a systematic review and meta-analysis. Balkan Med J 2021;38:7\u201312.10.5152\/balkanmedj.2021.20121"},{"key":"B278","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1200\/JCO.2003.12.093","article-title":"Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group study E3E93","volume":"21","author":"Wadler S","year":"2003","unstructured":"Wadler S, Levy DE, Lincoln ST,  Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group study E3E93. J Clin Oncol 2003;21:2110\u20132114.10.1200\/JCO.2003.12.093"},{"key":"B279","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ygyno.2004.07.035","article-title":"Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature","volume":"95","author":"Traina TA","year":"2004","unstructured":"Traina TA, Sabbatini P, Aghajanian C,  Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. Gynecol Oncol 2004;95:235\u2013241.10.1016\/j.ygyno.2004.07.035"},{"key":"B280","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1006\/gyno.2002.6804","article-title":"A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"87","author":"Miller DS","year":"2002","unstructured":"Miller DS, Blessing JA, Lentz SS,  A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2002;87:247\u2013251.10.1006\/gyno.2002.6804"},{"key":"B281","series-title":"Oncologist","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1634\/theoncologist.2010-0087","article-title":"Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents","volume":"15","author":"Moxley KM","year":"2010","unstructured":"Moxley KM, McMeekin DS. Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. Oncologist 2010;15:1026\u20131033.10.1634\/theoncologist.2010-0087"},{"key":"B282","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1200\/JCO.2002.08.171","article-title":"Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study","volume":"20","author":"Muggia FM","year":"2002","unstructured":"Muggia FM, Blessing JA, Sorosky J,  Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2002;20:2360\u20132364.10.1200\/JCO.2002.08.171"},{"key":"B283","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ygyno.2008.06.013","article-title":"A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group","volume":"111","author":"Garcia AA","year":"2008","unstructured":"Garcia AA, Blessing JA, Nolte S,  A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol Oncol 2008;111:22\u201326.10.1016\/j.ygyno.2008.06.013"},{"key":"B284","series-title":"Crit Rev Oncol Hematol","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.critrevonc.2010.07.013","article-title":"Developments in the systemic treatment of endometrial cancer","volume":"79","author":"Mountzios G","year":"2011","unstructured":"Mountzios G, Pectasides D, Bournakis E,  Developments in the systemic treatment of endometrial cancer. Crit Rev Oncol Hematol 2011;79:278\u2013292.10.1016\/j.critrevonc.2010.07.013"},{"key":"B285","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian C","year":"2011","unstructured":"Aghajanian C, Sill MW, Darcy KM,  Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011;29:2259\u20132265.10.1200\/JCO.2010.32.6397"},{"key":"B286","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the Keynote-028 study","volume":"35","author":"Ott PA","year":"2017","unstructured":"Ott PA, Bang YJ, Berton-Rigaud D,  Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the Keynote-028 study. J Clin Oncol 2017;35:2535\u20132541.10.1200\/JCO.2017.72.5952"},{"key":"B287","series-title":"Science","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le DT","year":"2017","unstructured":"Le DT, Durham JN, Smith KN,  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409\u2013413.10.1126\/science.aan6733"},{"key":"B288","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le DT","year":"2015","unstructured":"Le DT, Uram JN, Wang H,  PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509\u20132520.10.1056\/NEJMoa1500596"},{"key":"B289","article-title":"Prescribing information for pembrolizumab injection, for intravenous use","year":"2022","unstructured":"Prescribing information for pembrolizumab injection, for intravenous use. 2022. Accessed Jul 25, 2017. Available at: http:\/\/bit.ly\/2cTmItE"},{"key":"B290","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the Keynote-158 study","volume":"40","author":"O\u2019Malley DM","year":"2022","unstructured":"O\u2019Malley DM, Bariani GM, Cassier PA,  Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the Keynote-158 study. J Clin Oncol 2022;40:752\u2013761.10.1200\/JCO.21.01874"},{"key":"B291","series-title":"Ann Oncol","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah V","year":"2020","unstructured":"Subbiah V, Solit DB, Chan TA,  The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians. Ann Oncol 2020;31:1115\u20131118.10.1016\/j.annonc.2020.07.002"},{"key":"B292","series-title":"JCO Precis Oncol","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville R","year":"2017","unstructured":"Bonneville R, Krook MA, Kautto EA,  Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 2017;2017:PO.17.00073."},{"key":"B293","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ygyno.2019.06.016","article-title":"Comprehensive genomic profiling of recurrent endometrial cancer: implications for selection of systemic therapy","volume":"154","author":"Prendergast EN","year":"2019","unstructured":"Prendergast EN, Holman LL, Liu AY,  Comprehensive genomic profiling of recurrent endometrial cancer: implications for selection of systemic therapy. Gynecol Oncol 2019;154:461\u2013466.10.1016\/j.ygyno.2019.06.016"},{"key":"B294","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker V","year":"2020","unstructured":"Makker V, Taylor MH, Aghajanian C,  Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020;38:2981\u20132992.10.1200\/JCO.19.02627"},{"key":"B295","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker V","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A,  Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386:437\u2013448.10.1056\/NEJMoa2108330"},{"key":"B296","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1200\/JCO.19.00818","article-title":"Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study","volume":"38","author":"Azad NS","year":"2020","unstructured":"Azad NS, Gray RJ, Overman MJ,  Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. J Clin Oncol 2020;38:214\u2013222.10.1200\/JCO.19.00818"},{"key":"B297","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader AN","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E,  Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu. J Clin Oncol 2018;36:2044\u20132051.10.1200\/JCO.2017.76.5966"},{"key":"B298","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ygyno.2021.07.033","article-title":"Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2\/neu","volume":"163","author":"Tymon-Rosario J","year":"2021","unstructured":"Tymon-Rosario J, Siegel ER, Bellone S,  Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2\/neu. Gynecol Oncol 2021;163:93\u201399.10.1016\/j.ygyno.2021.07.033"},{"key":"B299","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1200\/JCO.2006.06.4907","article-title":"Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study","volume":"25","author":"Homesley HD","year":"2007","unstructured":"Homesley HD, Filiaci V, Markman M,  Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:526\u2013531.10.1200\/JCO.2006.06.4907"},{"key":"B300","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1006\/gyno.2000.6001","article-title":"A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"79","author":"Sutton G","year":"2000","unstructured":"Sutton G, Brunetto VL, Kilgore L,  A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2000;79:147\u2013153.10.1006\/gyno.2000.6001"},{"key":"B301","series-title":"Gynecol Oncol","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ygyno.2004.11.022","article-title":"Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study","volume":"96","author":"Sutton G","year":"2005","unstructured":"Sutton G, Kauderer J, Carson LF,  Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:630\u2013634.10.1016\/j.ygyno.2004.11.022"},{"key":"B302","series-title":"Cochrane Database Syst Rev","first-page":"CD006812","article-title":"Adjuvant radiotherapy and\/or chemotherapy after surgery for uterine carcinosarcoma","volume":"2013","author":"Galaal K","year":"2013","unstructured":"Galaal K, van der Heijden E, Godfrey K,  Adjuvant radiotherapy and\/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2013;2013:CD006812."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/2\/article-p181.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/2\/article-p181.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/2\/article-p181.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T15:12:56Z","timestamp":1676473976000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/2\/article-p181.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":302,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.0006","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}